



[Pharm Biol.](#) 2017; 55(1): 620–635.

Published online 2016 Dec 12. doi: [10.1080/13880209.2016.1262433](https://doi.org/10.1080/13880209.2016.1262433)

PMCID: PMC6130612

PMID: [27951737](#)

A systematic review of the active saikosaponins and extracts isolated from *Radix Bupleuri* and their applications

[Bochuan Yuan](#), [Rui Yang](#), [Yongsheng Ma](#), [Shan Zhou](#), [Xiaodong Zhang](#), and [Ying Liu](#)

[Author information](#) [Article notes](#) [Copyright and License information](#) [Disclaimer](#)

This article has been cited by other articles in PMC.

Abstract

[Go to:](#)

Introduction

With a 2000-year medicinal history, *Radix Bupleuri* (*Chai Hu* in Chinese) is believed to be one of the most important herbal medicines in China. The earliest record about *Radix Bupleuri* in China appeared in *Shen Nong Ben Cao Jing*, the first Chinese medical book, since then, *Radix Bupleuri* has been widely used in traditional Chinese medicine (TCM) for its effects of relieving exterior syndrome, clearing heat, regulating the liver-*qi*, and lifting yang-*qi* (Sen [1959](#)). It has been used in many traditional Chinese prescriptions, such as *Xiao Chai Hu Tang* and *Chai Hu Shu Gan Yin* to treat cold and liver diseases (Chen et al. [2011](#)). The roots are usually the medicinal parts of *Radix Bupleuri*, and which is often processed into pieces for easy use ([Figure 1](#)).



Figure 1.

Radix Bupleuri (a) and its pieces (b).

Bupleurum chinense DC. (Apiaceae) and *Bupleurum scorzonerifolium* Willd. are defined as the original plants of Radix Bupleuri in *Chinese Pharmacopeia* (National Pharmacopoeia Committee 2010). In fact, many other *Bupleurum* species are also used as Radix Bupleuri in East Asia, such as *Bupleurum falcatum* L., which is officially listed in *Japanese Pharmacopeia* (Saiko in Japanese) (Japanese Pharmacopoeia Editorial Board 2011), and *Bupleurum yinchowense* Shan and Li, which is recorded in some provincial *Pharmacopeia* of China (The Inner Mongolia Autonomous Region Health Department 1988; Food and Drug Administration of Gansu Province 2008).

These *Bupleurum* medicinal plants are widely distributed in the northern hemisphere (Judd 2008), and also commonly used in Eurasia and North Africa for their medicinal properties

(Mabberley 2008). As shown in Figure 2, they are perennial herbs with compound umbels, yellowish or rarely purplish bisexual flowers, containing five stamens, cremocarps, and simple, long, slender leaves (Figure 2).




Figure 2.

Bupleurum chinense DC. (a) Shows the compound umbels and simple, long, slender leaves, (b) shows the yellowish bisexual flowers of compound umbels.

With the development of modern pharmacology, many valuable and important activities of Radix Bupleuri have been discovered, such as anti-inflammatory (Xie et al. 2012), antitumor (Liu & Li 2014), antidepressant (Jin et al. 2013), antiviral (Chiang et al. 2003), hepatoprotection (Wang et al. 2013a), immunoregulation (Ying et al. 2014), and neuromodulation activities (Zhou et al. 2014). All

of these potent effects are due to its various secondary metabolites, especially saikosaponins, the content of which is up to 7% of the total dry weight of *Radix Bupleuri* roots (Ashour & Wink [2011](#)). To date, over 100 glycosylated oleanane-type saponins have been isolated and identified from *Radix Bupleuri* (Pistelli et al. [1993](#); Ebata et al. [1996](#)), and some of them have been demonstrated possessing bioactive properties both *in vitro* and *in vivo*. Therefore, reviewing and summarizing the pharmacological activities and mechanisms of saikosaponins from *Radix Bupleuri* is meaningful and important to obtain new insights for further research and development of *Radix Bupleuri*. In addition, since extracts are the main source of Chinese patent medicines containing *Radix Bupleuri*, their pharmacological properties and mechanisms are also summarized. Moreover, the applications and toxicity studies are discussed to provide a basis for further studies concerning the safety and efficacy of *Radix Bupleuri*.

In this paper, six main databases, PubMed, Web of Science, Science Direct, Research Gate, Academic Journals, and Google Scholar were used as information sources through the inclusion of the search terms ‘*Radix Bupleuri*’, ‘*Bupleurum*’, ‘saikosaponins’, ‘*Radix Bupleuri* preparation’, and their combinations, mainly from the year 2008 to 2016 without language restriction. As a result, we searched 296 papers and a total of 128 references were included in the present work.

[Go to:](#)

Purified saikosaponins from *Radix Bupleuri*

In recent years, over 100 different triterpenoid saponins have been isolated from *Radix Bupleuri*, among them saikosaponin a (SSa), saikosaponin d (SSd), saikosaponin c (SSc) and saikosaponin b₂ (SSb₂) ([Figure 3](#)) are believed to be responsible for the most pharmacological activities of *Radix Bupleuri* (Liu et al. [2002](#); Huang et al. [2013](#)). Saikosaponins are oleanane type triterpenoid saponins and divided into seven types according to different aglycones. SSa, SSd and SSc are epoxy-ether saikosaponins (type I), while SSb₂, with a different aglycone, is heterocyclic diene saikosaponin (type II) (Lin et al. [2013](#)).




Figure 3.

The structures of SSa, SSd, SSc and SSb₂.

[Go to:](#)

SSa

SSa, one of the most important active saikogenins in Radix Bupleuri (Liang et al. 2014), plays a significant role in anti-inflammatory (Wu et al. 2008, 2010; Han et al. 2011; Lu et al. 2012b; Chen et al. 2013b; Wang et al. 2013b; Zhu et al. 2013; Fu et al. 2015; Kim et al. 2015; Zhao et al. 2015a; Zhou et al. 2015), antitumor (Tsai et al. 2002; Wang et al. 2010a, 2010b), antiviral (Cheng et al. 2006; Chen et al. 2015), neuromodulation (Yu et al. 2012; Xie et al. 2013; Yoon et al. 2012, 2013; Zhou et al. 2014), and immunoregulation (Sun et al. 2009) activities. The various pharmacological activities, mechanisms, models and applications of SSa are given in [Table 1](#).

Table 1.

The various pharmacological activities, mechanisms, models, and applications of SSa.

Pharmacological activities of SSa	Tissue	Models/ cells	In <i>vivo/vitro</i>	Mechanisms	Applications	References
Anti-inflammatory activity	Adipocytes	3T3-L1 cells	<i>In vitro</i>	SSa inhibits the expression of inflammatory genes and is a potent inhibitor of NF- κ B activation.	Obesity-associated inflammation	(Kim et al. 2015)
	Ileum	Male Wistar rats	<i>In vivo</i>	SSa suppresses the production of TNF- α and IL-6 and inhibits the nucleotide-binding oligomerization domain 2 (NOD2)/NF- κ B signalling pathway.	Sepsis	(Zhao et al. 2015a)
	Liver	LX-2	<i>In vitro</i>	SSa down-regulates BMP-4 expression and inhibits	Liver fibrosis	(Wang et al. 2013b)

Pharmacological activities of SSa	Tissue	Models/ cells	<i>In vivo/vitro</i>	Mechanisms	Applications	References
-----------------------------------	--------	---------------	----------------------	------------	--------------	------------

hepatic stellate cell activation.

Macrophages RAW 264.7 *In vitro* SSa regulates inflammatory mediators and suppresses the MAPK and NF- κ B signalling pathways.

Lipopolysaccharide (LPS)-induced inflammation

Macrophages RAW264.7 *In vitro* SSa inhibits receptor activator of the nuclear factor- κ B ligand (RANKL)-induced I κ B α phosphorylation, p65 phosphorylation and NF- κ B luciferase activity.

Osteoporosis

Pharmacological activities of SSa	Tissue	Models/ cells	In <i>vivo/vitro</i>	Mechanisms	Applications	References
Vascular tissue	HUVEC s	HUVEC s	<i>In vitro</i>	SSa dose-dependently inhibits the production of ROS, TNF- α , IL-8, COX-2 and iNOS in LPS-stimulated HUVECs.	Oxidative damage	(Fu et al. 2015)
Liver	HSC-T6	HSC-T6	<i>In vitro</i>	SSa decreases the expressions of ERK1/2, PDGFR, TGF- β 1R, α -smooth muscle actin, and connective tissue growth factor to inhibit proliferation and activation of HSCs.	Liver inflammation and fibrogenesis	(Chen et al. 2013b)
Macroph ages	RAW26 4.7	RAW26 4.7	<i>In vitro</i>	SSa inhibits the activation of NF- κ B, iNOS, COX-2 and	LPS-induced inflammation	(Lu et al. 2012a)

Pharmacological activities of SSa	Tissue	Models/ cells	<i>In vivo/vitro</i>	Mechanisms	Applications	References
-----------------------------------	--------	---------------	----------------------	------------	--------------	------------

pro-inflammatory cytokines TNF- α and IL-6.

Inflammatory tissue HMC-1 In vitro SSa decreases the expression of IL-6, IL-1 β and TNF- α and suppresses NF- κ B signal pathway. Anti-inflammation (Han et al. [2011](#))

Liver Sprague-Dawley rats *In vivo* SSa inhibits the expression of hepatic proinflammatory cytokines and NF- κ B signal pathway and increases the expression of anti-inflammatory cytokine IL-10. Inhibition of liver injury (Wu et al. [2008, 2010](#))

Pharmacological activities of SSa	Tissue	Models/ cells	In <i>vivo/vitro</i>	Mechanisms	Applications	References
	Human monocytes	THP-1 leukemia cells	<i>In vitro</i>	SSa inhibits oxLDL-induced activation of AKT and NF-kappaB, assembly of NLRP3 inflammasome and production of pro-inflammatory cytokines.	Atherosclerosis	(He et al. 2016)
Neuroregulation	Hippocampal tissue	Sprague-Dawley rats	<i>In vivo</i>	SSa inhibits NMDA receptor current and persistent sodium current.	Epilepsy	(Yu et al. 2012)
	CA1 neurons	Sprague-Dawley rats	<i>In vivo</i>	SSa exerts selectively enhancing effects on I A.	Epilepsy	(Xie et al. 2013)

Pharmacological activities of SSa	Tissue	Models/ cells	<i>In vivo/vitro</i>	Mechanisms	Applications	References
-----------------------------------	--------	---------------	----------------------	------------	--------------	------------

Spinal cord tissues Chronic constriction ion injury rats *In vivo* SSa inhibits the activation of p38 MAPK and NF- κ B signalling pathways in spinal cord.

Chronic constriction injury (Zhou et al. 2014)

Hippocampus Sprague-Dawley rats *In vivo* SSa attenuates cocaine-reinforced behaviour through activation of GABA(B) receptors.

Morphine-reinforced behaviour (Yoon et al. 2012, 2013)

Nervous tissue Sprague-Dawley rats *In vivo* SSa counteracts the inflammatory response and neurological function deficits via an anti-inflammatory response and

Nerve injury (Mao et al. 2016)

Pharmacological activities of SSa	Tissue	Models/ cells	<i>In vivo/vitro</i>	Mechanisms	Applications	References
-----------------------------------	--------	---------------	----------------------	------------	--------------	------------

inhibition of
the MAPK
signalling
pathway.

Nervous tissue	Sprague-Dawley rats	<i>In vivo</i>	SSa inhibits this addiction by regulating GABA(B) receptor system.	Drug addiction	(Maccioni et al. 2016)
----------------	---------------------	----------------	--------------------------------------------------------------------	----------------	-----------------------------------------

Antitumor activity	Different cancer cells	A549, SKOV3, HeLa and Siha	<i>In vitro</i>	SSa sensitizes cancer cells to cisplatin through ROS - mediated apoptosis.	Cancer cell cytotoxicity	(Wang et al. 2010a)
--------------------	------------------------	----------------------------	-----------------	----------------------------------------------------------------------------	--------------------------	--------------------------------------

Glioma	C6 glioma cells	<i>In vitro</i>	SSa enhances the enzymatic activities of GS and CNP.	C6 glioma cells proliferation	(Tsai et al. 2002)
--------	-----------------	-----------------	------------------------------------------------------	-------------------------------	-------------------------------------

Pharmacological activities of SSa	Tissue	Models/ cells	In <i>vivo/vitro</i>	Mechanisms	Applications	References
-----------------------------------	--------	---------------	----------------------	------------	--------------	------------

Antiviral activity	Human fetal lung fibroblast	Human coronavi rus 229E	<i>In vitro</i>	SSa intervenes in the early stage of viral replication, such as absorption and penetration.	Coronavirus infection	(Cheng et al. 2006)
	Lung tissue	Influenza A virus infected A549	<i>In vitro</i>	SSa attenuates viral replication, aberrant pro-inflammatory cytokine production and lung histopathology.	Pathological influenza virus infections	(Chen et al. 2015)

Immunoregulation	Lymphoid tissue	Sprague-Dawley rats	<i>In vivo</i>	SSa inhibits the proliferation and activation of T cells and causes the G0/G1 arrest as well as the induction of apoptosis via	Inflammatory and autoimmune diseases	(Sun et al. 2009)
------------------	-----------------	---------------------	----------------	--------------------------------------------------------------------------------------------------------------------------------	--------------------------------------	------------------------------------



Pharmacological activities of SSa	Tissue	Models/ cells	<i>In vivo/vitro</i>	Mechanisms	Applications	References
-----------------------------------	--------	---------------	----------------------	------------	--------------	------------

mitochondrial pathway.

[Open in a separate window](#)

Anti-inflammatory activity

Among all of the pharmacological activities of SSa, the most important one is anti-inflammatory activity. SSa develops its anti-inflammatory activity mainly by inhibiting some inflammation-associated cytokines, proteins and enzymes, and regulating inflammation-related signal pathways, such as nuclear factor-κB (NF-κB) pathway and mitogen-activated protein kinase (MAPK) pathway. In order to better explain the molecular mechanisms of the anti-inflammatory activity of SSa, [Figures 4\(a,b\)](#) are provided to describe its NF-κB pathway and MAPK pathway.



[Open in a separate window](#)

Figure 4.

The molecular mechanisms of the anti-inflammatory activity of SSa. (a) shows the NF- κ B pathway, (b) shows the MAPK pathway.

In general, SSa inhibits the expression of pro-inflammatory cytokines, including tumor necrosis factor α (TNF- α), transforming growth factor- β 1R (TGF- β 1R), interleukin 1 β (IL-1 β), IL-6, and IL-8, and increases the expression of anti-inflammatory cytokine TGF- β 1 and IL-10 (Wu et al. [2008](#), [2010](#); Han et al. [2011](#); Lu et al. [2012a](#); Zhu et al. [2013](#); Fu et al. [2015](#); Kim et al. [2015](#); Zhao et al. [2015a](#)). SSa exerts inhibiting effect on inflammatory associated proteins and enzymes, such as inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2) (Lu et al. [2012b](#); Zhu et al. [2013](#); Fu et al. [2015](#); Kim et al. [2015](#)), extracellular matrix-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) (Chen et al. [2013b](#); Zhu et al. [2013](#); Zhou et al. [2015](#)), and it also suppresses particular proteins, bone morphogenetic protein 4 (BMP-4) (Wang et al. [2013b](#)), platelet-derived growth factor receptor 1 (PDGFR1) (Chen et al. [2013b](#)) and toll-like receptor 4 (TLR4) (Fu et al. [2015](#)) to exert particular effects (Wang et al. [2013b](#)).

NF- κ B pathway is an important signal pathway in inflammatory process (Bannon et al. [2015](#)). SSa attenuates inflammation mainly by inhibiting the activation of NF- κ B pathway (Wu et al. [2008](#), [2010](#); Han et al. [2011](#); Lu et al. [2012a](#); Kim et al. [2015](#); Zhao et al. [2015a](#); Zhou et al. [2015](#)). As shown in [Figure 4\(a\)](#), these inhibition effects are mainly reflected in two ways. One is inhibitory effects on phosphorylation of kinases, including I κ B α , p65 (Zhu et al. [2013](#); Kim et al. [2015](#); Zhou et al. [2015](#)), p38 (Han et al. [2011](#); Chen et al. [2013b](#); Zhou et al. [2015](#)), JNK (Zhu et al. [2013](#); Zhou et al. [2015](#)), and Akt (He et al. [2016](#)), and the other is blocking translocation of nuclear factors, including NF- κ B (Lu et al. [2012a](#); Zhu et al. [2013](#); Kim et al. [2015](#)) and NF- κ B/Rel A(Han et al. [2011](#)). The above two inhibition effects are marked by triangle in [Figure 4\(a\)](#).

As shown in [Figure 4\(b\)](#), SSa also has an inhibiting effect on MAPK pathway. It downregulates the phosphorylation of three key kinase, p38 MAPK, c-JNK, and ERK 1/2, which are located in the

downstream of MAPK pathway and marked by triangle symbol in [Figure 4\(b\)](#).

For studying the anti-inflammatory activity of SSa, it has been applied to mouse macrophage cells RAW264.7 (Zhou et al. [2015](#)), human umbilical vein endothelial cells (HUVECs) (Fu et al. [2015](#)), mouse embryonic fibroblasts 3T3-L1 (Kim et al. [2015](#)), hepatic stellate cells (HSCs) (Chen et al. [2013b](#)), and human mast cells (HMCs) (Han et al. [2011](#)) *in vitro*, and has been applied to the livers of Sprague-Dawley rats (Wu et al. [2010](#)) and Wistar rats (Zhao et al. [2015a](#)) *in vivo*.

Neuroregulation activity

SSa plays a significant role on neuroregulation. It exerts antiepileptic mainly by inhibiting *N*-methyl-D-aspartic acid (NMDA) receptor current, persistent sodium current (Yu et al. [2012](#)) and inactivating K⁺ current (Xie et al. [2013](#)). It inhibits the activation of p38 MAPK, NF- κ B signaling pathways to attenuate neuropathic pain (Zhou et al. [2014](#)), and activates γ -aminobutyric acid (GABA) receptor B to attenuate cocaine-reinforced behavior (Yoon et al. [2012, 2013](#)) and drug addiction (Maccioni et al. [2016](#)). It also counteracts the inflammatory response and neurological function deficits via an anti-inflammatory response and inhibition of the MAPK signaling pathway to ease nerve injury (Mao et al. [2016](#)). SSa has been applied to the hippocamp, CA1 neurons, and spinal cord tissues of Sprague-Dawley rats (Mao et al. [2016](#); Maccioni et al. [2016](#); Yu et al. [2012](#); Xie et al. [2013](#); Yoon et al. [2012, 2013](#)), and chronic constriction injury rats (Zhou et al. [2014](#)) *in vivo*, which determined its potential application in epilepsy, chronic constriction injury, nerve injury, and drug addiction.

Anti-tumor activity

SSa exhibits antitumor activity *in vitro* by sensitizing cancer cells to cisplatin, such as human lung adenocarcinoma cells A549, ovarian cancer cells SKOV3, and cervix cancer cells Hela and Siha, through reactive oxygen species (ROS)-mediated apoptosis (Wang et al. [2010a](#)) and enhancing the enzymatic activities of glutamine synthetase (GS) and 2',3'-cyclic nucleotide 3'-phosphohydrolase (CNP) in rat C6 glioma cells (Tsai et al. [2002](#)). Thus, the

combination of SSa with cisplatin could be an effective therapeutic strategy against cancer.

Antiviral activity

SSa has generally inhibitory effects against human coronavirus 229E (Cheng et al. 2006) and influenza A virus (Chen et al. 2015). It exerts antiviral activity mainly through interference in the early stage of viral replication, such as absorption and penetration (Chen et al. 2015), and attenuating aberrant pro-inflammatory cytokine production (Cheng et al. 2006). These two viruses are cultured in human cells, human fetal lung fibroblasts MRC-5 and A549 cells, respectively.

Immunoregulation activity

SSa inhibits the proliferation and activation of T cells and causes the G0/G1 cells arrest as well as the induction of apoptosis via mitochondrial pathway to exhibit its immunoregulation effect in Sprague-Dawley rats (Sun et al. 2009). This may herald a novel approach for further studies of SSa as a candidate for the treatment of autoimmune diseases.

[Go to:](#)

SSd

SSd is the epimer of SSa, they have the same basal structure. So, it has some similar pharmacological activities with SSa, such as anti-inflammatory (Lu et al. 2012b), antitumor (Chen et al. 2013a), and immunoregulation activities (Sun et al. 2009; Ying et al. 2014). However, SSd also possesses some specific pharmacological activities, such as anti-allergic (Hao et al. 2012) and anti-apoptosis activities (Li et al. 2014b). The various pharmacological activities, mechanisms, models and applications of SSd are listed in [Table 2](#).

Table 2.

The various pharmacological activities, mechanisms, models, and applications of SSd.

Pharmacological activities of SSd	Tissue	Models/cells	In vivo/vitro	Mechanisms	Applications	References
Antitumor activity	Liver	Sprague Dawley rats	<i>In vivo</i>	SSd inhibits the activation of CCAAT/enhancer binding protein β (C/EBP β) and COX-2.	Human hepatocellular carcinoma	(Lu et al. 2012b)
	Thyroid	ARO, 8305C, SW1736	<i>In vitro</i>	SSd promotes cell apoptosis and induced G1-phase cell cycle arrest.	Human undifferentiated thyroid carcinoma	(Liu & Li 2014)
	Liver	SMMC7721	<i>In vitro</i>	SSd suppresses the expression of COX-2 through the p-STAT3/hypoxia inducible factor-1 α (HIF-1 α) pathway.	Human hepatocellular carcinoma	(He et al. 2014)

Pharmacological activities of SSd	Tissue	Models/cells	<i>In vivo/vitro</i>	Mechanisms	Application	References

Prostate carcinoma cells DU145 *In vitro* SSd has effects on induction of apoptosis and cell cycle arrest at G0/G1 phase. (Yao et al. 2014)

Different cancer cells HeLa, HepG2 *In vitro* SSd suppresses TNF- α - induced NF- κ B activation and its target genes expression to inhibit cancer cell proliferation, invasion, angiogenesis and survival. (Wong et al. 2013a)

Lung carcinoma A549 *In vitro* SSd induces apoptosis and blocked cell cycle progression by (Hsu et al. 2004a)

Pharmacological activities of SSd	Tissue	Models/cells	In vivo/vitro	Mechanisms	Application	References
------------------------------------------	---------------	---------------------	----------------------	-------------------	--------------------	-------------------

activating Fas/FasL pathway in the G1 phase in A549 cells.

Liver	HepG2, 2.2.15	<i>In vitro</i>	SSd induces the apoptosis through the activation of caspases-3 and caspases-7.	Human hepatocellular carcinoma	(Chiang et al. 2003)
-------	---------------	-----------------	--------------------------------------------------------------------------------	--------------------------------	----------------------

Liver	Hep3B	<i>In vitro</i>	SSd induces apoptosis in Hep3B cells through the caspase-3 - independent pathways.	Human hepatocellular carcinoma	Zhou 2003
-------	-------	-----------------	------------------------------------------------------------------------------------	--------------------------------	-----------

Breast carcinoma tissue	MCF-7	<i>In vitro</i>	SSd activates oestrogen response element (ERE)-luciferase	Acting as a weak phytoestrogen.	(Wang et al. 2010a)
-------------------------	-------	-----------------	-----------------------------------------------------------	---------------------------------	---------------------

Pharmacological activities of SSd	Tissue	Models/cells	In vivo/vitro	Mechanisms	Applications	References
------------------------------------------	---------------	---------------------	----------------------	-------------------	---------------------	-------------------

activity via the ER α -mediated pathway.

Liver SMMC-7721, HepG2 *In vitro* SSd has a radiosensitizing effect on hepatoma cells under hypoxic conditions by inhibiting HIF-1 α expression. Radiotherapy sensitizes hepatoma cells to radiotherapy by inhibiting HIF-1 α expression. (Wang et al. 2014a, 2014b)

Different cancer cells HeLa, MCF-7 *In vitro* SSd induces autophagy through the formation of autophagosomes by inhibiting SERCA. Apoptosis-resistant cancer cells (Wong et al. 2013b)

Anti-inflammatory activity Inflammatory tissue RAW264.7 *In vitro* SSd has inhibitory effects on NF- κ B activation and iNOS, LPS-induced inflammatory (Lu et al. 2012a)

Pharmacological activities of SSd	Tissue	Models/cells	<i>In vivo/vitro</i>	Mechanisms	Application	References

COX-2 and pro-inflammatory cytokines including TNF- α and IL-6.

Hepatic stellate cells HSC-T6 *In vitro* SSd decreases the expressions of extracellular matrix-regulated kinase 1/2 (ERK1/2), PDGFR, TGF- β 1R, α -smooth muscle actin, TGF- β 1 and connective tissue growth factor. Liver inflammation and fibrogenesis (Chen et al. 2013a)

Human acute monocytic THP-1 *In vitro* SSd inhibits selectin-L-selectin-mediated (Jang et al. 2014)

Pharmacological activities of SSd	Tissue	Models/cells	In vivo/vitro	Mechanisms	Applications	References
leukaemia cells				mediated cell adhesion.	cell adhesion	
Liver	C57/BL6 rats	<i>In vivo</i>	SSd down-regulates NF- κ B and STAT3-mediated inflammatory signal pathway.	SSd down-regulates NF- κ B and STAT3-mediated inflammatory signal pathway.	Hepatotoxicity and liver injury	(Liu et al. 2014a)
Liver	Hepatic fibrosis rats	<i>In vivo</i>	SSd down-regulates liver TNF- α , IL-6 and NF- κ B p65 expression and increases I κ B- α activity.	SSd down-regulates liver TNF- α , IL-6 and NF- κ B p65 expression and increases I κ B- α activity.	Hepatic fibrosis	(Dang et al. 2007)
Kidney	LLC-PK1	<i>In vitro</i>	SSd increases the activity and expression of anti-oxidant enzymes (SOD, CAT,	SSd increases the activity and expression of anti-oxidant enzymes (SOD, CAT,	Oxidative damage in the kidney	(Zhang et al. 2014)

Pharmacological activities of SSd	Tissue	Models/cells	In vivo/vitro	Mechanisms	Applications	References
------------------------------------------	---------------	---------------------	----------------------	-------------------	---------------------	-------------------

GPx) and

HSP72.

Nervous tissue C6 rat glioma cells *In vitro* SSd possesses a dual effect: an inhibition of PGE2 production without a direct inhibition of cyclooxygenase activity and an elevation of $[Ca^{2+}]_i$.

Inflammation in C6 rat glioma cells (Kodama et al. 2003)

Lung VILI rats *In vivo* SSd decreases the expression of pro-inflammatory cytokines including MIP-2, IL-6 and TNF- α and elevates the expression of anti-inflammatory

Lung injury (Wang et al. 2015)

Pharmacological activities of SSd	Tissue	Models/cells	<i>In vivo/vitro</i>	Mechanisms	Application	References
				mediators, such as TGF- β 1 and IL-10.		

Renal tubular epithelial cells NRK-52E *In vitro* SSd attenuates oxidative injury via upregulation of SirT₃. High glucose induced kidney injury (Zhao et al. 2015b)

Kidney HK-2 *In vitro* SSd represses ROS-mediated activation of MAPK and NF- κ B signal pathways. DDP-induced kidney injury (Ma et al. 2015)

Immunoregulation Lymphoid tissue Mouse T cells *In vitro* SSd inhibits the T cell proliferation and activation through the NF- κ B, NF-AT and AP-1 signal pathways, and it also inhibits T cell-mediated autoimmune conditions (Wong et al. 2009)

Pharmacological activities of SSd	Tissue	Models/cells	In vivo/vitro	Mechanisms	Applications	References
------------------------------------------	---------------	---------------------	----------------------	-------------------	---------------------	-------------------

the cytokine secretion and IL-2 receptor expression.

Monocyte-derived dendritic cells *In vitro* SSd reduces the differentiation of human DCs and promotes DCs maturation and increases the function of mature DCs.

Anti-allergic activity Lymphoid tissue Rat basophilic leukemia-2H3 cells *In vitro* SSd suppresses the intracellular calcium mobilization and tyrosine phosphorylation, thereby prevents gene activation of Soybean allergy (Hao et al. 2012)

Pharmacological activities of SSD	Tissue	Models/cells	<i>In vivo/vitro</i>	Mechanisms	Application	References
------------------------------------------	---------------	---------------------	----------------------	-------------------	--------------------	-------------------

Cdc42 and c-Fos.

Neuroregulation on Neuronal cells PC12 *In vitro* SSD regulates mitochondrial and nuclear GR translocation, partial reversal of mitochondrial dysfunction, inhibition of the mitochondrial apoptotic pathway, and selective activation of the GR-dependent survival pathway.

Against corticosterone-induced apoptosis. (Li et al. 2014b)

Neuronal cells PC12 *In vitro* SSD reduces apoptosis by removing ROS Neuronal PC12 cells oxidative stress (Lin et al. 2016)


Pharmacological activities of SSd	Tissue	Models/cells	In vivo/vitro	Mechanisms	Applications	References
						s

and blocking MAPK-dependent oxidative damage.

[Open in a separate window](#)

Antitumor activity

The most important pharmacological activity of SSd is antitumor activity. In order to better explain this important activity, [Figure 5](#) is provided to describe its molecular mechanisms. SSd exhibits the antitumor activity mainly through activation and inhibition, which are marked by rectangle and triangle in [Figure 5](#), respectively. First, SSd increases the expression of p53 and Bax (Liu & Li [2014](#); Wang et al. [2014a, 2014b](#); Yao et al. [2014](#)), activates caspases apoptosis pathway, including the activation of caspases-3 and caspases-7 (Chiang et al. [2003](#); Chou et al. [2003](#)) and the Fas/FasL apoptotic system (Hsu et al. [2004a](#)) in several cancer cell lines *in vitro*, which are marked by rectangle in [Figure 5](#). Second, SSd decreases the expression of B cell lymphoma 2 (Bcl-2) family proteins (Liu & Li [2014](#); Wang et al. [2014a, 2014b](#); Yao et al. [2014](#)), suppresses the expression of COX-2, which has been shown to be involved in carcinogenesis (Lu et al. [2012b](#); He et al. [2014](#)), and also potentiates TNF- α -mediated cell death via suppression of TNF- α -induced NF- κ B activation (Wong et al. [2013a](#)), which are marked by triangle in [Figure 5](#). Besides, SSd also suppresses MCF-7 cells proliferation through the estrogenic effect of SSd by the estrogen receptor (Wang et al. [2010a, 2010b](#)), and induces autophagy of apoptosis-resistant cancer cells through the formation of autophagosomes by inhibiting sarcoplasmic/endoplasmic reticulum Ca²⁺ ATPase pump (SERCA) (Wong et al. [2013b](#)).



Pathway Diagram Keys

- Inhibited transcription factor or gene
- Activated transcription factor, caspases or up-regulation gene
- Inhibited transcription pathway
- Promoted transcription pathway
- Inhibited stimulatory modification
- Promoted stimulatory modification

[Open in a separate window](#)

[Figure 5.](#)

The molecular mechanisms of the anti-tumor activity of SSd.

To date, SSd has been applied in human hepatoma cells HepG2, Hep3B (Chou et al. [2003](#)), SMMC7721 (He et al. [2014](#)), and 2.2.15 cells (Chiang et al. [2003](#)), anaplastic thyroid cancers cells ARO, 8305C, and SW1736 (Liu & Li [2014](#)), prostate carcinoma cells DU145 (Yao et al. [2014](#)), lung cancer cells A549 (Hsu et al. [2004a](#)), cervical carcinoma cells Hela (Wong et al. [2013a, 2013b](#)), and breast carcinoma cells MCF-7 (Wang et al. [2010b](#)) *in vitro*, and applied in diethylnitrosamine (DEN)-treated Sprague Dawley rats *in vivo* (Lu et al. [2012b](#)), and which indicates its potential in treatment of cancer.

Anti-inflammatory activity

SSd also possesses an evident anti-inflammatory activity, and the mechanisms are similar to SSa, as shown in [Figure 4\(a\)](#). On the cytokines level, SSd suppresses pro-inflammatory cytokines including TNF- α , IL-6, macrophage inflammatory protein-2 (MIP-2), and elevates the expression of anti-inflammatory cytokines, such as TGF- β 1 and IL-10 (Lu et al. [2012a](#); Ma et al. [2015](#); Wang et al. [2015](#)). On the level of proteins and enzymes, it inhibits the activity and expression of iNOS, COX-2, ERK1/2, PDGFR, α -smooth muscle actin, NF- κ B, and signal transducer and activator of transcription 3 (STAT3) (Chen et al. [2013a](#); Liu et al. [2014a](#)), and increases the activity and expression of inhibitor of nuclear factor of κ B- α ($I\kappa B-\alpha$) (Dang et al. [2007](#)), SirT3 (Zhao L et al. [2015](#)), anti-oxidant enzymes (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) and heat shock protein (HSP) 72 (Zhang et al. [2014](#)). Furthermore, SSd also exhibits its particular anti-inflammatory pattern by inhibiting selectin-mediated cell adhesion (Jang et al. [2014](#)), and possessing a dual effect, an inhibition of prostaglandin E₂ (PGE₂) production without a direct inhibition of cyclooxygenase activity and an elevation of Ca²⁺ (Kodama et al. [2003](#)).

According to the above reports, SSa and SSd are very similar in mechanisms of anti-inflammation, however, there are still several different points, which are listed in [Table 3](#). SSa is able to inhibit phosphorylation of three key kinase in MAPK pathway, which was

not reported in researches of SSd. While SSd is able to restrain selectin-mediated cell adhesion, PGE₂ production, and elevate the Ca²⁺ level intracellular, which were not reported in researches of SSA

Table 3.

The similarities and differences of SSA and SSd in mechanisms of anti-inflammation.

The possible mechanisms of anti-inflammation	SSa	SSd
Inhibiting pro-inflammatory cytokines and promoting anti-inflammatory cytokines	✓	✓
Inhibiting activity of enzymes associated with inflammation	✓	✓
Inhibiting activation of NF-κB pathway	✓	✓
Inhibiting activation of MAPK pathway	✓	X
Inhibiting selectin-mediated cell adhesion	X	✓
Inhibiting PGE2 production and elevating Ca ²⁺ level intracellular	X	✓

For a better understanding of SSd's anti-inflammatory activity, it has been applied to mouse leukaemic monocyte macrophage macroph RAW264.7 (Lu et al. [2012a](#)), hepatic stellate cells HSC-T6 (Chen et al. [2013a](#)), human acute monocytic leukemia cells THP-1 (Jang et al. [2014](#)), pig kidney proximal tubular cells LLC-PK1 (Zhang et al. [2014](#)), C6 rat glioma cells (Kodama et al. [2003](#)), renal tubular epithelial cells NRK-52E (Zhao et al. [2015b](#)), and HK-2 (Ma et al. [2015](#)) *in vitro*, and acetaminophen-induced hepatotoxicity C57/BL6 rats (Liu et al. [2014a](#)), hepatic fibrosis model rats (Dang

et al. 2007), and ventilator-induced lung injury (VILI) rats (Wang et al. 2015) *in vivo*, which determined its potential application for treating hepatitis, pneumonia, nephritis and other inflammation.

Immunoregulation activity

SSd plays its immunoregulation role by regulating the NF- κ B, nuclear factor-AT (NF-AT), and activator protein 1 (AP-1) signal pathways to inhibit T cell proliferation and activation (Wong et al. 2009). It has been applied to condylomata acuminate, a disease caused by human papilloma virus (HPV), by reducing the differentiation of human monocyte-derived dendritic cells (DCs) and promoting DCs maturation and increasing the function of mature DCs (Ying et al. 2014).

Anti-allergic activity

β -Conglycinin has been identified as a potential diagnostic marker for severe basophil-dependent allergic reactions to soybean. SSd possesses anti-allergic activity by inhibiting β -conglycinin-induced rat basophilic leukemia-2H3 cell degranulation and suppressing critical incidents in the signal transduction pathway (Hao et al. 2012). Hence it could become an effective herbal therapy for alleviating soybean allergy.

Neuroregulation activity

Neuronal oxidative stress injury has been proven to be associated with many neurodegenerative diseases. SSd exerts neuroregulation activity on neuronal PC12 cells by inhibiting the translocation of the glucocorticoid receptor (GR) to the mitochondria, restoring mitochondrial function, down-regulating the expression of pro-apoptotic-related signalling events and up-regulating anti-apoptotic-related signalling events (Li et al. 2014b). In H₂O₂-induced oxidative stress PC12 cells, SSd effectively decreases oxidative stress injury by blocking H₂O₂-induced phosphorylation of ERK, JNK, and p38MAPK to exert neuroregulation activity (Lin et al. 2016). Thus, SSd treatment is an effective method for treating neurodegenerative diseases.

[Go to:](#)

SSc

SSc has the same basal structure with SSa and SSd. They are epoxy-ether saikosaponins belonging to type I saikosaponins (Shin et al. [2015](#)). However, the pharmacological activities of SSc are far weaker than SSa and SSd. To date, reports about pharmacological activities of SSc are very limited. SSc exerts anti-apoptotic effects on HUVECs by suppressing caspase-3 activation and subsequent degradation of focal adhesion kinase (FAK) and other cell adhesion signals, which is similar to SSa (Lee et al. [2014](#)). Thus, it will be a promising therapeutic candidate for the treatment of vascular endothelial cell injury and cellular dysfunction. Besides, SSc completely prevents the development of nephritis (Chen et al. [2008](#)), but the mechanism of this activity is still unclear. In addition, SSc exhibits antiviral activity by inhibiting hepatitis B virus (HBV) DNA replication (Chiang et al. [2003](#)).

[Go to:](#)

SSb₂

SSb₂ has a different basic structure compared to SSa, SSd, and SSc. SSb₂ is a type II saikosaponin, and it is not considered as a main active compound in *Radix Bupleuri*. However, SSb₂ has fairly inhibitory effects against corona virus and hepatitis C virus (HCV). It mainly interferes with the early stages of viral replication, such as absorption and penetration of the virus (Cheng et al. [2006](#)). SSb₂ potently inhibits HCV infection at non-cytotoxic concentrations through efficient inhibition on early HCV entry, including neutralization of virus particles, preventing viral attachment, and inhibiting viral entry/fusion (Lin et al. [2014](#)).

[Go to:](#)

Radix Bupleuri extracts

Many *Bupleurum* medicinal plants are used as Radix Bupleuri. The pharmacological activities of extracts from seven *Bupleurum* species, *B. chinense* (Wen et al. [2011](#)), *B. falcatum* (Lee et al. [2012a](#)), *Bupleurum marginatum* Wall. ex DC. (Ashour et al. [2014](#)), *B. yinchowense* (Li et al. [2013](#)), *Bupleurum kaoi* L. (Hsu et al. [2004a](#), [2004b](#)), *B. scorzonerifolium* (Cheng

et al. 2005), and *Bupleurum longiradiatum* Turcz. (You et al. 2002), are given in Table 4. They have been demonstrated to possess antitumor (Cheng et al. 2003, 2005; Hsu et al. 2004a, 2004b; Chen et al. 2005; Kang et al. 2008; Ashour et al. 2014), antiviral (Wen et al. 2011), anti-inflammatory (Lee et al. 2010; Nakahara et al. 2011), anti-hyperthyroidism (Kim et al. 2012b) and neuroregulation effects (Xie et al. 2006; Lee et al. 2009, 2012b; Li et al. 2013; Liu et al. 2014b).

Table 4.

The pharmacological activities and mechanisms of extracts from different *Bupleurum* species.

Species	Extractive e	Extractio n method fractions	Activities	Mechanisms	References
<i>B. chinenses</i>	Aqueous extracts	Water decoction, 3 h	Antitumor activity	Enhancing 5- fluorouracil-induced cytotoxicity in HepG2 hepatoma cells and protecting normal blood lymphocytes.	(Kang et al. 2008)
		Water decoction, 3 h	Antiviral activity	Suppressing the effect on regulated activation normal T- cell expressed (RANTES) secretion.	(Wen et al. 2011)

Species	Extractive e	Extractio n method	Activities	Mechanisms	References
fractions					
	Water decoction, 3 h	Affect drug distribution	Inhibiting the activity of β -glucuronidase.	(Chen et al. 2014)	
	Methanol TSS extracts	Methanol, reflux, 4 h	Neuroregulation	Suppressing the abnormal activation of hippocampal astrocyte through inhibiting the overexpression of glial fibrillary acidic protein.	(Xie et al. 2006)
	95% methanol 5% pyridine, reflux, 4 h		TSS antagonizes the reserpine-induced akinesia, and ptosis in mice.	(Liu et al. 2014a)	
<i>B. falcatum</i>	Ethanol extracts	70% ethanol, reflux, 6 h	Anti-inflammatory activity	Inhibiting the expression and activation of both metal matrix proteinase (MMP)-2 and MMP-9 after spinal cord injury	(Lee et al. 2010)

Species	Extractive e	Extractio n method	Activities	Mechanisms	References
	fractions				
			(SCI) and the mRNA expressions of TNF- α , IL-1 β , COX-2, and iNOS.		
	80% ethanol, reflux, 6 h	Anti-depressant activity	Reducing depression and anxiety-like behaviors, possibly through central adrenergic mechanism.	(Lee et al. 2012a)	
	80% ethanol, reflux, 6h	Memory improvement	Attenuating IMO stress-induced loss of cholinergic immunoreactivity in the hippocampus.	(Lee et al. 2009)	
	Methanol extracts	Methanol, reflux, 4 h	Anti-depressant activity	The mechanism of this activity involves the serotonergic and noradrenergic systems.	(Kwon et al. 2010)

Species	Extractive method	Extraction method	Activities	Mechanisms	References
<i>B. scorzonerifolium</i>	Fractions	Methanol, reflux, 4 h	Anti-inflammatory activity	Decreasing the content of alanine transaminase (ALT) in blood serum of the liver injury rats.	(Nakahara et al. 2011)
	Aqueous extracts	Water decoction, 3 h	Anti-hyperthyroidism	Attenuating LT4-induced hyperthyroidisms and normalizing LT4-induced liver oxidative stresses and reducing liver and epididymal fat pad changes.	(Kim et al. 2012b)
	Acetone extracts	Acetone, reflux, 4 h	Antitumor activity	Inducing tubulin polymerization, and activates caspase-3 and caspase-9 in A549 cells, and these effects are related to ERK 1/2 activation and the apoptosis.	(Chen et al. 2005; Cheng et al. 2005)

Species	Extractive e	Extractio n method	Activities	Mechanisms	References
			Acetone, reflux, 4 h	Inhibiting telomerase activity and activation of apoptosis.	(Cheng et al. 2003)
<i>B. marginatum</i>	Methanol extracts	Methanol, reflux, 6 h	Anti-infective and antitumor activities	Methanol extracts show a significant anti-trypanosomal activity and moderate activity against <i>Streptococcus</i> <i>s pyogenes</i> and have the cytotoxicity inducing apoptosis.	(Ashour et al. 2014)
<i>B. longiradiatum</i>	Ethyl acetate extracts	Ethyl acetate, reflux, 4 h	Antiangiogenic activity	It has an inhibitory effect on the tube- like formation of HUVECs.	(You et al. 2002)
<i>B. yinchowense</i>	Ethanol TSS extracts	60% ethanol 0.5% ammonia reflux, 6 h	Neuroregulatio n	The neuroprotective mechanism relates with inhibiting the ER stress and the	(Li et al. 2013)

Species	Extractive e	Extractio n method	Activities	Mechanisms	References
	fractions				
	mitochondrial apoptotic pathways.				
<i>B. kaoi</i>	Methanol TSS	Methanol, reflux, 4 h extracts	Antitumor activity	The activity of the Fas/Fas ligand apoptotic system participates in the antiproliferative activity of TSS in A549 cells.	(Hsu et al. 2004b)
	Extracts from <i>B. kaoi</i> show potent antiproliferative effects on human A375.S2 melanoma cells.				
	Open in a separate window				

Five kinds of extraction agents, water, methanol, ethanol, acetone and ethyl acetate, have been used to extract effective fractions from Radix Bupleuri. Aqueous extracts of Radix Bupleuri are obtained by boiling at 80 °C for 3 h, and then evaporating and lyophilizing (Kang et al. [2008](#); Wen et al. [2011](#); Kim et al. [2012b](#); Chen et al. [2014](#)). The method to obtain methanol, ethanol, acetone and ethyl acetate extracts is reflux extraction (You et al. [2002](#); Cheng et al. [2005](#); Lee et al. [2010](#); Liu et al. [2014a](#)). To obtain methanol extracts, Radix Bupleuri is extracted twice by 100% methanol or 95% methanol with 5% pyridine at 70 °C for 4 h (Xie et al. [2006](#); Kwon et al. [2010](#);

Nakahara et al. 2011; Liu et al. 2014a; Ashour et al. 2014). To obtain ethanol extracts, Radix Bupleuri is extracted twice by 60% (Li et al. 2013), 70% (Lee et al. 2010) or 80% ethanol (Lee et al. 2012a) at room temperature for 6 h. To obtain acetone and ethyl acetate extracts, Radix Bupleuri is extracted three times by 100% acetone and 100% ethyl acetate at room temperature for 4 h (You et al. 2002; Cheng et al. 2005).

The pharmacological activities of extracts from *B. chinense* and *B. falcatum* have relative in-depth studies. The aqueous extracts of *B. chinense* possess three activities, antitumor activity on HepG2 hepatoma cells (Kang et al. 2008), antiviral activity on H1N1-infected A549 cells (Wen et al. 2011), and an activity to affect drug distribution (Chen et al. 2014). Methanol total saikosaponins (TSS) extracts of *B. chinense* have a neuroregulation effect (Xie et al. 2006; Liu et al. 2014a). In chronic kindling rats induced by pentetetrazole (PTZ), TSS of *B. chinense* inhibit glial fibrillary acidic protein (GFAP) over-expression and suppress the abnormal activation of hippocampal astrocyte (Xie et al. 2006). Anti-depressant activity of TSS is investigated by tail suspension test, forced swimming test, and reserpine antagonism test in mice, which demonstrate that it shortens the immobility time of mice in the tail suspension test in a somewhat dose-dependent manner (Liu et al. 2014a).

Both ethanol extracts and methanol extracts of *B. falcatum* have an anti-inflammatory effect (Lee et al. 2010; Nakahara et al. 2011) with similar mechanisms to SSa. They also possess an anti-depressant activity possibly through central adrenergic mechanism (Kwon et al. 2010; Lee et al. 2012a). Besides, the ethanol extracts of *B. falcatum* has its specific memory improvement activity by attenuating immobilization (IMO) stress-induced loss of cholinergic immunoreactivity in the hippocampus (Lee et al. 2009). The aqueous extracts of *B. falcatum* has an anti-hyperthyroidism activity by attenuating leukotriene-4 (LT4)-induced hyperthyroidisms, normalizing LT4-induced liver oxidative stresses and reducing liver and epididymal fat pad changes (Kim et al. 2012b).

The acetone extracts of *B. scorzonerifolium* exerts stronger antitumor activity on A549 cells mainly through inducing tubulin polymerization (Chen et al. 2005), activating caspase-3 and caspase-9 (Cheng et al. 2005), and inhibiting telomerase activity and

activation of apoptosis (Cheng et al. 2003). Methanol extracts of *B. marginatum* and *B. kaoi* have an antitumor activity by inducing apoptosis (Ashour et al. 2014) and activating the Fas/Fas ligand apoptotic system respectively (Hsu et al. 2004b), and extracts of *B. kaoi* have antitumor activity on human A375.S2 melanoma cells by inhibiting phosphorylation of JNK, p38 and p53, decreasing level of cytochrome c (Hu et al. 2016). What's more, the ethanol TSS extracts of *B. yinchowense* show antidepressant activity by inhibiting the estrogen receptor (ER) stress and the mitochondrial apoptotic pathways (Li et al. 2013), and the ethyl acetate extracts of *B. longiradiatum* exhibit an antiangiogenic activity by inhibiting the tube-like formation of HUVECs (You et al. 2002).

[Go to:](#)

Applications of Radix Bupleuri in TCM

Radix Bupleuri has been used for more than 2000 years in China since its first record in *Shen Nong Ben Cao Jing* (Xie et al. 2009). And now, it is officially listed in *Chinese Pharmacopeia*. In TCM, Radix Bupleuri is mainly used to treat liver diseases, alleviate cold fever, chills, chest pain, regulate menstruation, and improve uterine prolapsed (Zhou 2003). In particular, Radix Bupleuri also plays a significant role in the treatment of malaria (Xue et al. 1996). Importantly, Radix Bupleuri is usually used as monarch drug in many traditional Chinese prescriptions.

To date, Radix Bupleuri has been used in about 150 traditional Chinese prescriptions. Among them, *Xiao Chai Hu Tang*, *Chai Hu Gui Zhi Tang*, and *Xiao Yao San* are very famous in TCM. *Xiao Chai Hu* decoction, including Radix Bupleuri, pinellia (the tuber of *Pinellia ternata* (Thunb.) Breit., *Banxia* in Chinese) and skullcap (the root of *Scutellaria baicalensis* Georgi, *Huangqin* in Chinese), is used to treat malaria and jaundice. When Radix Bupleuri combines with cassia twig (the twig of *Cinnamomum cassia* Presl, *Guizhi* in Chinese), it is called *Chai Hu Gui Zhi* decoction which is often used for regulating liver-qi, clearing heat, and lifting yang qi. *Xiao Yao San*, composed of Radix Bupleuri, Poria (*Poria cocos* (Schw.) Wolf), Radix Paeoniae Alba (*Paeonia lactiflora* Pall.), Radix Angelicae Sinensis (*Angelica sinensis* (Oliv.) Diels), Rhizoma Atractylodis Macrocephalae (*Atractylodes macrocephala* Koidz.), Herba Menthae (*Mentha haplocalyx* Briq.), and Rhizoma Zingiberis

Recens (*Zingiber officinale* Rosc.), has been widely used in clinic for treating mental disorders, such as depression and irregular menstruation. In addition, combination with ginseng (*Panax ginseng* C.A.Mey.) and Radix Astragali (*Astragalus membranaceus* (Fisch.) Bge.). Radix Bupleuri is also used to treat hemorrhoids, anal and uterine complications, and diarrhea (1998; 1999; World Health Organization 1997). Inspired by the role in regulating metabolism and controlling *Yin/Yang* as mentioned in the traditional Chinese medicine, Radix Bupleuri is also widely used in Korea and Japan (Van & Wink 2004; Pan 2006).

[Go to:](#)

Applications of Radix Bupleuri in modern Chinese medicine

With the development of TCM modernization, more Radix Bupleuri preparations have been developed, such as *Xiao Chai Hu* tablets, *Chai Hu* dripping pills, *Chai Hu* injection and *Chai Hu Shu Gan* pills (Li et al. 2014a). The preparations from Radix Bupleuri approved by CFDA from June 2010 to October 2015 are given in [Table 5](#). Among them, *Chai Hu* injection is the first successful traditional Chinese medicine injection having been used in clinic since 1940s, which is widely used to treat fever caused by influenza or common cold and malaria (Zuo et al. 2013). Moreover, some new dosage forms of Radix Bupleuri have been prepared. A nasal temperature-sensitive *in situ* gel system is developed, which is more effective for the treatment of fever than the traditional nasal spray (Chen et al. 2010). Another benefit of this novel *in situ* gel is that it exhibits more noticeable antipyretic effects and remains much more time (Cao et al. 2007). Besides, the Radix Bupleuri suppositories is very suitable for kids without pain (Wang & Chen 2003).

Table 5.

The preparations from Bupleuri Radix approved by CFDA.

Components	Dosage forms	China Approved Drug Names (CADN)	Batch number	Approval date	Drug standard code
Radix Bupleuri extract, poly yamanashi ester-80, sodium chloride	Injection	<i>Chai Hu</i> Injection	Z61021126	07/2013	86902434000703
Radix Bupleuri dry extract	Tablet	<i>Chai Hu Cough Tablets</i>	Z42020845	06/2015	86901876000227
Radix Bupleuri, scutellaria, pinellia, dangshen, ginger, licorice and jujube	Tablet	<i>Xiao Chai Hu Tablets</i>	Z20023393	10/2015	86903050000405
Radix bupleuri, polyethylene glycol	Dripping Pill	<i>Chai Hu Dripping Pills</i>	Z20020053	07/2015	86900941000063
Radix Bupleuri, scutellaria, pinellia, dangshen, ginger, licorice and jujube	Decoction Pill	<i>Xiao Chai Hu Decoction Pills</i>	Z41021830	06/2015	86903082001340

Components	Dosage forms	China Approved Drug Names (CADN)	Batch number	Approval date	Drug standard code
Radix Bupleuri, scutellaria, pinellia, dangshen, ginger, licorice, jujube	Particle	<i>Xiao Chai Hu</i> Particles	Z34020723	05/2015	86904366000721
Radix Bupleuri, scutellaria, pinellia, dangshen, ginger, licorice, jujube	Capsule	<i>Xiao Chai Hu</i> Capsules	Z20090882	08/2014	86904641002884
Radix Bupleuri, scutellaria, rhubarb, immature bitter orange, pinellia, paeoniae, jujube, ginger	Particle	<i>Da Chai Hu</i> Particles	Z20080007	02/2013	86901622002642
Radix Bupleuri, tangerine peel, ligustici, rhizoma cyperi, hoveniadulcis, paeoniae, licorice	Pill	<i>Chai Hu Shu Gan</i> Pills	Z20073333	07/2015	86901174000103

Components	Dosage forms	China Approved Drug Names (CADN)	Batch number	Approval date	Drug standard code
Radix Bupleuri extract	Oral Liquid	<i>Chai Hu</i> Oral Liquid	Z20020107	06/2010	86903099000244
Radix Bupleuri, sileris, tangerine peel, paeoniae, licorice, ginger	Particle	<i>Zheng Chai Hu Yin</i> Particles	Z20003013	06/2015	86901622002086
Radix Bupleuri, sileris, tangerine peel, paeoniae, licorice, ginger	Capsule	<i>Zheng Chai Hu Yin</i> Capsules	Z20040013	07/2015	86904398000362
Radix Bupleuri, sileris, tangerine peel, paeoniae, licorice, ginger	Mist	<i>Zheng Chai Hu Yin</i> Mixture	Z20090749	06/2014	86901622002666
Radix Bupleuri, scutellaria, pinellia, dangshen, ginger, licorice and jujube	Effervescent tablet	<i>Xiao Chai Hu</i> Effervescent Tablets	Z20060458	11/2011	86900042000085

Components	Dosage forms	China Approved Drug Names (CADN)	Batch number	Approval date	Drug standard code
Radix Bupleuri extract, acetaminophen	Injection	Paracetamol and Bupleurum Injection	H52020518	09/2010	86905510000024

[Open in a separate window](#)

[Go to:](#)

Side effects of Radix Bupleuri

Radix Bupleuri is not defined as a toxic medicine in many official pharmacopeias, such as *Chinese Pharmacopeia* and *Japanese Pharmacopeia* (National Pharmacopoeia Committee [2010](#); Japanese Pharmacopoeia Editorial Board [2011](#)). However, in practical use, it exhibits liver, kidney, and blood system toxicity by taking a large dose for a long period, while it shows no side effect without overdose (Liu et al. [2012](#)). *Chai Hu* injection may cause a hypersensitivity-like response, hypokalemia and renal failure. And one case is reported to die from severe hypersensitivity shock (Wu et al. [2014](#)). So, the safety of Radix Bupleuri preparations is of great concern to us.

Saikosaponins and essential oils are believed to be the main compounds responsible for side effects of Radix Bupleuri (Liu et al. [2012](#)). Essential oils from *B. chinense* cause hepatic injury when the dosage is about 1.5–3.4 times of the clinical daily dosage of Radix Bupleuri oral liquid (Sun & Yang [2011](#)). Saikosaponins from *B. chinense* induce the hepatotoxicity by causing liver cell damage and necrosis administrating continuously to rats for 15 days (Huang et al. [2010](#)). SSd stimulates mitochondrial apoptosis in hepatocytes to exhibit its hepatotoxicity (Chen et al. [2013a](#)).

Extracts of Radix Bupleuri also show some side effects. Extracts of *B. chinense* induce hepatotoxicity damage through oxidative damage mechanism, and the hepatotoxicity damage caused by the

alcohol extracts is more serious than that caused by aqueous extracts (Lv et al. 2009). Furthermore, LD₅₀ (50% lethal dose) of the aqueous extracts of Radix Bupleuri after single oral treatment in female and male mice are considered to be over 2000 mg/kg (Kim et al. 2012a). In Kampo (Japanese traditional herbal) medicines, studies of some potential interactions between Radix Bupleuri and other drugs are considered, especially in prescriptions containing Radix Bupleuri, such as *Shosaikoto*, *Daisaikoto*, *Saikokeishito*, *Hochuekkito*, *Saibokuto* and *Saireito*. They may lead to anorexia, slight fever, and nausea (Ikegami et al. 2006).

Among other *Bupleurum* species, *B. longiradiatum* is a toxic herb in *Chinese Pharmacopeia* (National Pharmacopoeia Committee 2010), and it cannot be used as Radix Bupleuri. The main toxic compounds in *B. longiradiatum* are acetyl-bupleurotoxin, bupleurotoxin (Zhao et al. 1987) and polyene acetylene compounds, which are able to cause neurotoxicity (Chen et al. 1981).

[Go to:](#)

Discussion and perspective

Saikosaponins, especially SSa and SSd, are the main active compounds in Radix Bupleuri. They are also prescribed as the marker compounds to evaluate the quality of Radix Bupleuri in *Chinese Pharmacopeia* (National Pharmacopoeia Committee 2010). They possess evident anti-inflammatory, antitumor, neuroregulation, hepatoprotection, immunoregulation, antiviral, and antioxidative activities. And what need to emphasize is that SSa has a strongest anti-inflammatory effect, and SSd possesses a strongest antitumor effect compared with other saikosaponins, and both SSb₂ and SSC have a better antiviral activity than SSa and SSd, which proves that the activities of different saikosaponins have some extent tendency. Inspired by this feature, we speculate that purified saikosaponin has more concentrated pharmacological activities than extracts.

Recently, more preparations containing Radix Bupleuri have been developed, such as *Xiao Chai Hu* tablets, *Chai Hu* dripping pills, *Chai Hu* injection, and *Chai Hu Shu Gan* pills (Li et al. 2014a). In these preparations the extracts of Radix Bupleuri, especially

saikosaponins (Hu et al. 2011), are the main composition.

Although *B. chinense* and *B. scorzonerifolium* are the only two original plants of Radix Bupleuri in *Chinese Pharmacopeia*, many other *Bupleurum* species are often used as Radix Bupleuri in China. However, the extracts of *B. chinenses*, *B. falcatum*, *B. marginatum*, *B. yinchowense*, *B. kaoi*, *B. scorzonerifolium*, and *B.*

longiradiatum possess different pharmacological activities, such as the antitumor and antiviral activities of *B. chinenses* extracts, and the anti-inflammatory, anti-hyperthyroidism and neuroregulation activities of *B. falcatum* extracts. Because the quality, botanic characteristic and property, and pharmacological activities of different *Bupleurum* species are different, the standardization of Bupleuri Radix extracts is vital for the safe use of Radix Bupleuri.

In addition, there are many other compounds in Radix Bupleuri, such as polysaccharides and essential oils. Polysaccharides in Radix Bupleuri usually exert hepatoprotective and immunoregulation activities. The hepatoprotective effect of Radix Bupleuri polysaccharides is evaluated by measuring aspartate transaminase (AST), alanine transaminase, alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) activities in the plasma of mice (Zhao et al. 2012), and Radix Bupleuri polysaccharides inhibits complement activation on both the classical and alternative pathways (DI HY et al. 2013). The essential oils of Radix Bupleuri have strong antimicrobial (Ashour et al. 2009) and antifungal activities (Mohammadi et al. 2014). Besides, Radix Bupleuri also contains a little lignans, which exhibit antitumor (Ou et al. 2012) and hepatoprotective activities (Lee et al. 2011, 2012). Since polysaccharides (Tong et al. 2013; Wu et al. 2013) and essential oils (Liu et al. 2009; Yan et al. 2014) have been found to possess excellent pharmacological activities so far, we suppose that the quality evaluation method should be updated to meet the need of clinical therapy.

Radix Bupleuri also exhibits some security problems in the clinic. Since ‘*Xiao Chai Hu* Decoction event’ occurred in late 1980s in Japan, the clinical safety of Radix Bupleuri has been considered (Wu et al. 2014). The reasons of toxicity are complex and there is a great individual variation in the susceptibility to Radix Bupleuri. The current researches have shown that the toxicity of Radix Bupleuri mainly associated with dosage and drug administration time (Liu

et al. 2012). For example, SSd exhibits antitumor activity on carcinoma cell lines with dose-dependence, but when the dosage of SSd increased to a high level it would exert cytotoxicity (Zhang et al. 2015). Usually, Radix Bupleuri is believed to be safe in defined dose prescribed by pharmacopeia.

[Go to:](#)

Disclosure statement

All authors declare that they have no competing interests.

[Go to:](#)

References

1. Ashour ML, El-Readi M, Youns M, Mulyaningsih S, Sporer F, Efferth T, Wink M.. 2009. Chemical composition and biological activity of the essential oil obtained from *Bupleurum marginatum* (Apiaceae). J Pharm Pharmacol. 61:1079–1087. [[PubMed](#)] [[Google Scholar](#)]
2. Ashour ML, El-Readi MZ, Hamoud R, Eid SY, El AS, Nibret E, Herrmann F, Youns M, Tahrani A, Kaufmann D, et al. . 2014. Anti-infective and cytotoxic properties of *Bupleurum marginatum*. Chin Med. 9:4. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
3. Ashour ML, Wink M.. 2011. Genus *Bupleurum*: a review of its phytochemistry, pharmacology and modes of action. J Pharm Pharmacol. 63:305–321. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
4. Bannon A, Zhang SD, Schock BC, Ennis M.. 2015. Cystic fibrosis from laboratory to bedside: the role of A20 in NF- κ B-mediated inflammation. Med Princ Pract. 24:301–310. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
5. Cao SL, Chen E, Zhang QZ, Jiang XG.. 2007. A novel nasal delivery system of a Chinese traditional medicine, Radix Bupleuri, based on the concept of ion-activated *in situ* gel. Arch Pharm Res. 30:1014–1019. [[PubMed](#)] [[Google Scholar](#)]
6. Chen E, Chen J, Cao SL, Zhang QZ, Jiang XG.. 2010. Preparation of nasal temperature-sensitive *in situ* gel of Radix Bupleuri and evaluation of the febrile response

- mechanism. *Drug Dev Ind Pharm.* 36:490–496. [PubMed] [Google Scholar]
7. Chen J, Duan M, Zhao Y, Ling F, Xiao K, Li Q, Li B, Lu C, Qi W, Zeng Z, et al. . 2015. Saikosaponin A inhibits influenza A virus replication and lung immunopathology. *Oncotarget.* 6:42541–42556. [PMC free article] [PubMed] [Google Scholar]
 8. Chen L, Zhang F, Kong D, Zhu X, Chen W, Wang A, Zheng S.. 2013a. Saikosaponin D disrupts platelet-derived growth factor- β receptor/p38 pathway leading to mitochondrial apoptosis in human LO2 hepatocyte cells: a potential mechanism of hepatotoxicity. *Chem Biol Interact.* 206:76–82. [PubMed] [Google Scholar]
 9. Chen MF, Huang CC, Liu PS, Chen CH, Shiu LY.. 2013b. Saikosaponin A and saikosaponin D inhibit proliferation and migratory activity of rat HSC-T6 cells. *J Med Food.* 16:793–800. [PMC free article] [PubMed] [Google Scholar]
 10. Chen SM, Sato N, Yoshida M, Satoh N, Ueda S.. 2008. Effects of *Bupleurum scorzoneraefolium*, *Bupleurum falcatum*, and saponins on nephrotoxic serum nephritis in mice. *J Ethnopharmacol.* 116:397–402. [PubMed] [Google Scholar]
 11. Chen X, Liu X, Li Z, Sun M, Chu D, Sun Y.. 1981. The preliminary research on the toxicity of *Bupleurum longiradiatum*. *Chin Pharm J.* 1:62. [Google Scholar]
 12. Chen X, Yu T, Chen Z, Zhao R, Mao S.. 2014. Effect of saikosaponins and extracts of vinegar-baked Bupleuri Radix on the activity of β -glucuronidase. *Xenobiotica.* 44:785–791. [PubMed] [Google Scholar]
 13. Chen Y, Wang J, Yuan L, Zhou L, Jia X, Tan X.. 2011. Interaction of the main components from the traditional Chinese drug pair *Chaihu-Shaoyao* based on rat intestinal absorption. *Molecules.* 16:9600–9610. [PMC free article] [PubMed] [Google Scholar]
 14. Chen YL, Lin SZ, Chang WL, Cheng YL, Harn HJ.. 2005. Requirement for ERK activation in acetone extract identified from *Bupleurum scorzonerifolium* induced A549

- tumor cell apoptosis and keratin 8 phosphorylation. *Life Sci.* 76:2409–2420. [[PubMed](#)] [[Google Scholar](#)]
15. Cheng PW, Ng LT, Chiang LC, Lin CC.. 2006. Antiviral effects of saikosaponins on human coronavirus 229E in vitro. *Clin Exp Pharmacol Physiol.* 33:612–616. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
16. Cheng YL, Chang WL, Lee SC, Liu YG, Lin HC, Chen CJ, Yen CY, Yu DS, Lin SZ, Harn HJ.. 2003. Acetone extract of *Bupleurum scorzonerifolium* inhibits proliferation of A549 human lung cancer cells via inducing apoptosis and suppressing telomerase activity. *Life Sci.* 73:2383–2394. [[PubMed](#)] [[Google Scholar](#)]
17. Cheng YL, Lee SC, Lin SZ, Chang WL, Chen YL, Tsai NM, Liu YC, Tzao C, Yu DS, Harn HJ.. 2005. Anti-proliferative activity of *Bupleurum scorzonerifolium* in A549 human lung cancer cells in vitro and in vivo. *Cancer Lett.* 222:183–193. [[PubMed](#)] [[Google Scholar](#)]
18. Chiang LC, Ng LT, Liu LT, Shieh DE, Lin CC.. 2003. Cytotoxicity and anti-hepatitis B virus activities of saikosaponins from *Bupleurum* species. *Planta Med.* 69:705–709. [[PubMed](#)] [[Google Scholar](#)]
19. Chou CC, Pan SL, Teng CM, Guh JH.. 2003. Pharmacological evaluation of several major ingredients of Chinese herbal medicines in human hepatoma Hep3B cells. *Eur J Pharm Sci.* 19:403–412. [[PubMed](#)] [[Google Scholar](#)]
20. Dang SS, Wang BF, Cheng YA, Song P, Liu ZG, Li ZF.. 2007. Inhibitory effects of saikosaponin-D on CCl₄-induced hepatic fibrogenesis in rats. *World J Gastroenterol.* 13:557–563. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
21. DI HY, Zhang YY, Chen DF.. 2013. Isolation of an anti-complementary polysaccharide from the root of *Bupleurum chinense* and identification of its targets in complement activation cascade. *Chin J Nat Med.* 11:177–184. [[PubMed](#)] [[Google Scholar](#)]
22. Ebata N, Nakajima K, Hayashi K, Okada M, Maruno M.. 1996. Saponins from the root of *Bupleurum falcatum*. *Phytochemistry.* 41:895–901. [[PubMed](#)] [[Google Scholar](#)]

23. Food and Drug Administration of Gansu Province. 2008. Chinese medicinal materials standard of Gansu province. Lanzhou, China: Gansu Culture Press. [[Google Scholar](#)]
24. Fu Y, Hu X, Cao Y, Zhang Z, Zhang N.. 2015. Saikosaponin A inhibits lipopolysaccharide-oxidative stress and inflammation in Human umbilical vein endothelial cells via preventing TLR4 translocation into lipid rafts. Free Radic Biol Med. 89:777–785. [[PubMed](#)] [[Google Scholar](#)]
25. Han NR, Kim HM, Jeong HJ.. 2011. Inactivation of cystein-aspartic acid protease (caspase)-1 by saikosaponin A. Biol Pharm Bull. 34:817–823. [[PubMed](#)] [[Google Scholar](#)]
26. Hao Y, Piao X, Piao X.. 2012. Saikosaponin-d inhibits β -conglycinin induced activation of rat basophilic leukemia-2H3 cells. Int Immunopharmacol. 13:257–263. [[PubMed](#)] [[Google Scholar](#)]
27. He D, Wang H, Xu L, Wang X, Peng K, Wang L, Liu P, Qu P.. 2016. Saikosaponin A attenuates oxidized LDL uptake and prompts cholesterol efflux in THP-1 cells. J Cardiovasc Pharmacol. 67:510–518. [[PubMed](#)] [[Google Scholar](#)]
28. He S, Lu G, Hou H, Zhao Z, Zhu Z, Lu X, Chen J, Wang Z.. 2014. Saikosaponin-d suppresses the expression of cyclooxygenase-2 through the phospho-signal transducer and activator of transcription 3/hypoxia-inducible factor-1 α pathway in hepatocellular carcinoma cells. Mol Med Rep. 10:2556–2562. [[PubMed](#)] [[Google Scholar](#)]
29. Hsu YL, Kuo PL, Lin CC.. 2004a. The proliferative inhibition and apoptotic mechanism of saikosaponin D in human non-small cell lung cancer A549 cells. Life Sci. 75:1231–1242. [[PubMed](#)] [[Google Scholar](#)]
30. Hsu YL, Kuo PL, Weng TC, Yen MH, Chiang LC, Lin CC.. 2004b. The antiproliferative activity of saponin-enriched fraction from *Bupleurum kaoi* is through Fas-dependent apoptotic pathway in human non-small cell lung cancer A549 cells. Biol Pharm Bull. 27:1112–1115. [[PubMed](#)] [[Google Scholar](#)]

31. Hu SC, Lee IT, Yen MH, Lin CC, Lee CW, Yen FL.. 2016. Anti-melanoma activity of *Bupleurum chinense*, *Bupleurum kaoi* and nanoparticle formulation of their major bioactive compound saikosaponin-d. *J Ethnopharmacol.* 179:432–442. [[PubMed](#)] [[Google Scholar](#)]
32. Hu Y, Pu J, Liang W, Zheng J, Wei K.. 2011. The assaying of saikosaponins and saikosaponin D in the extracts of Radix Bupleuri. *Chin J Trad Med Sci Technol.* 18:46–47. [[Google Scholar](#)]
33. Huang W, Lv Z, Sun R.. 2013. Research development on chemincal compositions in *Bupleurum chinense* related with efficacy and toxicity. *Chin J Pharmacovigil.* 10:545–548. [[Google Scholar](#)]
34. Huang W, Sun R, Zhang Z.. 2010. ‘Dose-time-toxicity’ relationship study on hepatotoxicity caused by multiple dose of total *Bupleurum* saponin crude extracts to rats. *Zhongguo Zhong Yao Za Zhi.* 35:3344–3347. [[PubMed](#)] [[Google Scholar](#)]
35. Ikegami F, Sumino M, Fujii Y, Akiba T, Satoh T.. 2006. Pharmacology and toxicology of *Bupleurum* root-containing Kampo medicines in clinical use. *Hum Exp Toxicol.* 25:481–494. [[PubMed](#)] [[Google Scholar](#)]
36. Jang MJ, Kim YS, Bae EY, Oh TS, Choi HJ, Lee JH, Oh HM, Lee SW.. 2014. Saikosaponin D isolated from *Bupleurum falcatum* inhibits selectin-mediated cell adhesion. *Molecules.* 19:20340–20349. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
37. Japanese Pharmacopoeia Editorial Board 2011. The Japanese pharmacopoeia. Tokyo, Japan: Japanese Ministry of Health. [[Google Scholar](#)]
38. Jin X, Zhang Y, Li Q, Zhao J.. 2013. Mechanisms underlying the beneficial effects of Kaiyu Granule for depression. *Neural Regen Res.* 8:3241–3248. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
39. Judd W. 2008. Plant systematics: a phylogenetic approach, 3rd ed Sunderland, MA: Sinauer Associates. [[Google Scholar](#)]
40. Kang SJ, Lee YJ, Kim BM, Kim YJ, Woo HD, Jeon HK, Chung HW.. 2008. Effect of Bupleuri Radix extracts on the

- toxicity of 5-fluorouracil in HepG2 hepatoma cells and normal human lymphocytes. Basic Clin Pharmacol Toxicol. 103:305–313. [PubMed] [Google Scholar]
41. Kim KH, Gam CO, Choi SH, Ku SK.. 2012a. Mouse single oral dose toxicity test of bupleuri radix aqueous extracts. Toxicol Res. 28:11–18. [PMC free article] [PubMed] [Google Scholar]
42. Kim SM, Kim SC, Chung IK, Cheon WH, Ku SK.. 2012b. Antioxidant and protective effects of *Bupleurum falcatum* on the l-thyroxine-induced hyperthyroidism in rats. Evid Based Complement Alternat Med. 2012:578497. [PMC free article] [PubMed] [Google Scholar]
43. Kim SO, Park JY, Jeon SY, Yang CH, Kim MR.. 2015. Saikosaponin A, an active compound of Radix Bupleuri, attenuates inflammation in hypertrophied 3T3-L1 adipocytes via ERK/NF- κ B signaling pathways. Int J Mol Med. 35:1126–1132. [PubMed] [Google Scholar]
44. Kodama Y, Xiaochuan L, Tsuchiya C, Ohizumi Y, Yoshida M, Nakahata N.. 2003. Dual effect of saikogenin d: in vitro inhibition of prostaglandin E2 production and elevation of intracellular free Ca²⁺ concentration in C6 rat glioma cells. Planta Med. 69:765–767. [PubMed] [Google Scholar]
45. Kwon S, Lee B, Kim M, Lee H, Park HJ, Hahm DH.. 2010. Antidepressant-like effect of the methanolic extract from *Bupleurum falcatum* in the tail suspension test. Prog Neuropsychopharmacol Biol Psychiatry. 34:265–270. [PubMed] [Google Scholar]
46. Lee B, Shim I, Lee H, Hahm DH.. 2009. Effect of *Bupleurum falcatum* on the stress-induced impairment of spatial working memory in rats. Biol Pharm Bull. 32:1392–1398. [PubMed] [Google Scholar]
47. Lee B, Yun HY, Shim I, Lee H, Hahm DH.. 2012a. *Bupleurum falcatum* prevents depression and anxiety-like behaviors in rats exposed to repeated restraint stress. J Microbiol Biotechnol. 22:422–430. [PubMed] [Google Scholar]
48. Lee JY, Kim HS, Oh TH, Yune TY.. 2010. Ethanol extract of *Bupleurum falcatum* improves functional

- recovery by inhibiting matrix metalloproteinases-2 and -9 activation and inflammation after spinal cord injury. *Exp Neurobiol.* 19:146–154. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
49. Lee TF, Lin YL, Huang YT.. 2011. Kaerophyllin inhibits hepatic stellate cell activation by apoptotic bodies from hepatocytes. *Liver Int.* 31:618–629. [[PubMed](#)] [[Google Scholar](#)]
50. Lee TF, Lin YL, Huang YT.. 2012b. Protective effects of kaerophyllin against liver fibrogenesis in rats. *Eur J Clin Invest.* 42:607–616. [[PubMed](#)] [[Google Scholar](#)]
51. Lee TH, Chang J, Kim BM.. 2014. Saikosaponin c inhibits lipopolysaccharide-induced apoptosis by suppressing caspase-3 activation and subsequent degradation of focal adhesion kinase in human umbilical vein endothelial cells. *Biochem Biophys Res Commun.* 445:615–621. [[PubMed](#)] [[Google Scholar](#)]
52. Li C, Liu Y, Liu Y, Zhang S, Li P, Shi X, Xu D, Liu T.. 2014a. Advances in research of chemical constituents and active constituents of *Bupleurum chinense* DC. *Chinese Arch Trad Chinese Med.* 32:2674–2677. [[Google Scholar](#)]
53. Li ZY, Guo Z, Liu YM, Liu XM, Chang Q, Liao YH, Pan RL.. 2013. Neuroprotective effects of total saikosaponins of *Bupleurum yinchowense* on corticosterone-induced apoptosis in PC12 cells. *J Ethnopharmacol.* 148:794–803. [[PubMed](#)] [[Google Scholar](#)]
54. Li ZY, Jiang YM, Liu YM, Guo Z, Shen SN, Liu XM, Pan RL.. 2014b. Saikosaponin D acts against corticosterone-induced apoptosis via regulation of mitochondrial GR translocation and a GR-dependent pathway. *Prog Neuropsychopharmacol Biol Psychiatry.* 53:80–89. [[PubMed](#)] [[Google Scholar](#)]
55. Liang Z, Oh K, Wang Y, Yi T, Chen H, Zhao Z.. 2014. Cell type-specific qualitative and quantitative analysis of saikosaponins in three *Bupleurum* species using laser microdissection and liquid chromatography-quadrupole/time of flight-mass spectrometry. *J Pharm Biomed Anal.* 97:157–165. [[PubMed](#)] [[Google Scholar](#)]

56. Lin LT, Chung CY, Hsu WC, Chang SP, Hung TC, Shields J, Russell RS, Lin CC, Li CF, Yen MH, et al. . 2014. Saikosaponin B2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry. *J Hepatol.* 62:541–548. [\[PubMed\]](#) [\[Google Scholar\]](#)
57. Lin TY, Chiou CY, Chiou SJ.. 2013. Putative genes involved in saikosaponin biosynthesis in *Bupleurum* species. *Int J Mol Sci.* 14:12806–12826. [\[PMC free article\]](#) [\[PubMed\]](#) [\[Google Scholar\]](#)
58. Lin X, Wu S, Wang Q, Shi Y, Liu G, Zhi J, Wang F.. 2016. Saikosaponin D reduces HO-induced PC12 cell apoptosis by removing ROS and blocking MAPK-dependent oxidative damage. *Cell Mol Neurobiol.* 36:1365–1375. [\[PubMed\]](#) [\[Google Scholar\]](#)
59. Liu A, Tanaka N, Sun L, Guo B, Kim JH, Krausz KW, Fang Z, Jiang C, Yang J, Gonzalez FJ.. 2014a. Saikosaponin D protects against acetaminophen-induced hepatotoxicity by inhibiting NF- κ B and STAT3 signaling. *Chem Biol Interact.* 223:80–86. [\[PMC free article\]](#) [\[PubMed\]](#) [\[Google Scholar\]](#)
60. Liu K, Lota ML, Casanova J, Tomi F.. 2009. The essential oil of *Bupleurum fruticosum* L. from Corsica: a comprehensive study. *Chem Biodivers.* 6:2244–2254. [\[PubMed\]](#) [\[Google Scholar\]](#)
61. Liu Q, Tan L, Bai Y, Liang H, Zhao Y.. 2002. The research of genus *Bupleurum* saponins nearly 10 years. *China J Chinese Materia Med.* 27:7–11. [\[PubMed\]](#) [\[Google Scholar\]](#)
62. Liu RY, Li JP.. 2014. Saikosaponin-d inhibits proliferation of human undifferentiated thyroid carcinoma cells through induction of apoptosis and cell cycle arrest. *Eur Rev Med Pharmacol Sci.* 18:2435–2443. [\[PubMed\]](#) [\[Google Scholar\]](#)
63. Liu Y, Cao C, Ding H.. 2014b. Pharmacological experimental study of the anti-depressant effect of total saikosaponins. *Afr J Tradit Complement Altern Med.* 11:280–284. [\[PMC free article\]](#) [\[PubMed\]](#) [\[Google Scholar\]](#)

64. Liu Y, Liu X, Pan R.. 2012. The research of Radix bupleuri toxic effect. Chinese Tradit Patent Med. 34:1148–1151. [[Google Scholar](#)]
65. Lu CN, Yuan ZG, Zhang XL, Yan R, Zhao YQ, Liao M, Chen JX.. 2012a. Saikosaponin A and its epimer saikosaponin D exhibit anti-inflammatory activity by suppressing activation of NF- κ B signaling pathway. Int Immunopharmacol. 14:121–126. [[PubMed](#)] [[Google Scholar](#)]
66. Lu XL, He SX, Ren MD, Wang YL, Zhang YX, Liu EQ.. 2012b. Chemopreventive effect of saikosaponin-d on diethylnitrosamine-induced hepatocarcinogenesis: involvement of CCAAT/enhancer binding protein β and cyclooxygenase-2. Mol Med Rep. 5:637–644. [[PubMed](#)] [[Google Scholar](#)]
67. Lv L, Huang W, Yu X, Ren H, Sun R.. 2009. Comparative research of different *Bupleurum chinense* composition to influence of hepatotoxicity of rats and oxidative damage mechanism. Zhongguo Zhong Yao Za Zhi. 34:2364–2368. [[PubMed](#)] [[Google Scholar](#)]
68. Ma X, Dang C, Kang H, Dai Z, Lin S, Guan H, Liu X, Wang X, Hui W.. 2015. Saikosaponin-D reduces cisplatin-induced nephrotoxicity by repressing ROS-mediated activation of MAPK and NF- κ B signalling pathways. Int Immunopharmacol. 28:399–408. [[PubMed](#)] [[Google Scholar](#)]
69. Mabberley D. 2008. Mabberley's plant-book: a portable dictionary of plants, their classification and uses. New York, USA: Cambridge University Press. [[Google Scholar](#)]
70. Maccioni P, Lorrai I, Carai MA, Riva A, Morazzoni P, Mugnaini C, Corelli F, Gessa GL, Colombo G.. 2016. Reducing effect of saikosaponin a, an active ingredient of *Bupleurum falcatum*, on alcohol self-administration in rats: possible involvement of the GABA receptor. Neurosci Lett. 621:62–67. [[PubMed](#)] [[Google Scholar](#)]
71. Mao X, Miao G, Tao X, Hao S, Zhang H, Li H, Hou Z, Tian R, Lu T, Ma J, et al. . 2016. Saikosaponin a protects TBI rats after controlled cortical impact and the underlying

- mechanism. Am J Transl Res. 8:133–141. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
72. Mohammadi A, Nazari H, Imani S, Amrollahi H.. 2014. Antifungal activities and chemical composition of some medicinal plants. J Mycol Med. 24:e1–e8. [[PubMed](#)] [[Google Scholar](#)]
73. Nakahara Y, Okawa M, Kinjo J, Nohara T.. 2011. Oleanene glycosides of the aerial parts and seeds of *Bupleurum falcatum* and the aerial parts of *Bupleurum rotundifolium*, and their evaluation as anti-hepatitis agents. Chem Pharm Bull (Tokyo). 59:1329–1339. [[PubMed](#)] [[Google Scholar](#)]
74. National Pharmacopoeia Committee 2010. Pharmacopoeia of People's Republic of China. Part 1. Beijing, China: Chemical Industry Press. [[Google Scholar](#)]
75. Ou JP, Lin HY, Su KY, Yu SL, Tseng IH, Chen CJ, Hsu HC, Chan DC, Sophia CY.. 2012. Potential therapeutic role of Z-isochaihulactone in lung cancer through induction of apoptosis via notch signaling. Evid Based Complement Alternat Med. 2012:809204. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
76. Pan S. 2006. *Bupleurum* species: scientific evaluation and clinical applications. Boca Raton, UK: CRC/Taylor & Francis. [[Google Scholar](#)]
77. Pistelli L, Bilia AR, Marsili A, De Tommasi N, Manunta A.. 1993. Triterpenoid saponins from *Bupleurum fruticosum*. J Nat Prod. 56:240–244. [[PubMed](#)] [[Google Scholar](#)]
78. Sen L. 1959. Shennong's herbal. Shanghai, China: Shanghai Technology and Health Press. [[Google Scholar](#)]
79. Shin JE, Kim HJ, Kim KR, Lee SK, Park J, Kim H, Park KK, Chung WY.. 2015. Type I saikosaponins A and D inhibit osteoclastogenesis in bone marrow-derived macrophages and osteolytic activity of metastatic breast cancer cells. Evid Based Complement Alternat Med. 2015:582437. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
80. Sun R, Yang Q.. 2011. Experimental study on the ‘dosage-time-toxicity’ relationship of chronic

- hepatotoxicity induced by volatile oil from *Bupleurum chinense* in rats. *Pharmacol Clin Chinese Materia Med.* 7:49–51. [[Google Scholar](#)]
81. Sun Y, Cai TT, Zhou XB, Xu Q.. 2009. Saikosaponin A inhibits the proliferation and activation of T cells through cell cycle arrest and induction of apoptosis. *Int Immunopharmacol.* 9:978–983. [[PubMed](#)] [[Google Scholar](#)]
82. The Inner Mongolia Autonomous Region Health Department 1988. Chinese medicinal materials standard of Inner Mongolia Autonomous Region. Hohhot, China: Inner Mongolia Medical Press. [[Google Scholar](#)]
83. Tong H, Tian D, He Z, Liu Y, Chu X, Sun X.. 2013. Polysaccharides from *Bupleurum chinense* impact the recruitment and migration of neutrophils by blocking fMLP chemoattractant receptor-mediated functions. *Carbohydr Polym.* 92:1071–1077. [[PubMed](#)] [[Google Scholar](#)]
84. Tsai YJ, Chen IL, Horng LY, Wu RT.. 2002. Induction of differentiation in rat C6 glioma cells with saikosaponins. *Phytother Res.* 16:117–121. [[PubMed](#)] [[Google Scholar](#)]
85. Van WB, Wink M.. 2004. Medicinal plants of the world: an illustrated scientific guide to important medicinal plants and their uses. Portland, USA: Timber Press. [[Google Scholar](#)]
86. Wang BF, Lin S, Bai MH, Song LQ, Min WL, Wang M, Yang P, Ma HB, Wang XJ.. 2014a. Effects of SSd combined with radiation on inhibiting SMMC-7721 hepatoma cell growth. *Med Sci Monit.* 20:1340–1344. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
87. Wang BF, Wang XJ, Kang HF, Bai MH, Guan HT, Wang ZW, Zan Y, Song LQ, Min WL, Lin S, et al. . 2014b. Saikosaponin D enhances radiosensitivity of hepatoma cells under hypoxic conditions by inhibiting hypoxia-inducible factor-1 α . *Cell Physiol Biochem.* 33:37–51. [[PubMed](#)] [[Google Scholar](#)]
88. Wang C, Zhang T, Cui X, Li S, Zhao X, Zhong X.. 2013a. Hepatoprotective effects of a Chinese herbal formula, longyin decoction, on carbon-tetrachloride-

- induced liver injury in chickens. Evid Based Complement Alternat Med. 2013:392743. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
89. Wang HW, Liu M, Zhong TD, Fang XM.. 2015. Saikosaponin-d attenuates ventilator-induced lung injury in rats. Int J Clin Exp Med. 8:15137–15145. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
90. Wang L, Chen Y.. 2003. Study on preparation procedure of suppositoria Radix Bupleuri for kids. Zhong Yao Cai. 26:512–514. [[PubMed](#)] [[Google Scholar](#)]
91. Wang P, Ren J, Tang J, Zhang D, Li B, Li Y.. 2010a. Estrogen-like activities of saikosaponin-d in vitro: a pilot study. Eur J Pharmacol. 626:159–165. [[PubMed](#)] [[Google Scholar](#)]
92. Wang Q, Zheng XL, Yang L, Shi F, Gao LB, Zhong YJ, Sun H, He F, Lin Y, Wang X.. 2010b. Reactive oxygen species-mediated apoptosis contributes to chemosensitization effect of saikosaponins on cisplatin-induced cytotoxicity in cancer cells. J Exp Clin Cancer Res. 29:159. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
93. Wang X, Wang Q, Burczynski FJ, Kong W, Gong Y.. 2013b. Saikosaponin A of *Bupleurum chinense* (*Chaihu*) elevates bone morphogenetic protein 4 (BMP-4) during hepatic stellate cell activation. Phytomedicine. 20:1330–1335. [[PubMed](#)] [[Google Scholar](#)]
94. Wen S, Huifu X, Hao H.. 2011. *In vitro* anti-influenza A H1N1 effect of extract of Bupleuri Radix. Immunopharmacol Immunotoxicol. 33:433–437. [[PubMed](#)] [[Google Scholar](#)]
95. Wong VK, Li T, Law BY, Ma ED, Yip NC, Michelangeli F, Law CK, Zhang MM, Lam KY, Chan PL, et al. . 2013a. Saikosaponin-d, a novel SERCA inhibitor, induces autophagic cell death in apoptosis-defective cells. Cell Death Dis. 4:e720. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
96. Wong VK, Zhang MM, Zhou H, Lam KY, Chan PL, Law CK, Yue PY, Liu L.. 2013b. Saikosaponin-d enhances the anticancer potency of TNF- α via overcoming its undesirable response of activating NF-Kappa B signalling

- in cancer cells. *Evid Based Complement Alternat Med.* 2013:745295. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
97. Wong VK, Zhou H, Cheung SS, Li T, Liu L.. 2009. Mechanistic study of saikosaponin-d (Ssd) on suppression of murine T lymphocyte activation. *J Cell Biochem.* 107:303–315. [[PubMed](#)] [[Google Scholar](#)]
98. World Health Organization 1997. Medicinal plants in China: a selection of 150 commonly used species. Manila, Philippines: World Health Organization: Regional Office for the Western Pacific. [[Google Scholar](#)]
99. World Health Organization 1998. Medicinal plants in the Republic of Korea: information on 150 commonly used medicinal plants. Manila, Philippines: World Health Organization: Regional Office for the Western Pacific. [[Google Scholar](#)]
100. World Health Organization 1999. WHO Monographs on selected medicinal plants. Geneva, Switzerland: World Health Organization [[Google Scholar](#)]
101. Wu J, Zhang YY, Guo L, Li H, Chen DF.. 2013. *Bupleurum* polysaccharides attenuates lipopolysaccharide-induced inflammation via modulating toll-like receptor 4 signaling. *PLoS One.* 8:e78051. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
102. Wu SJ, Lin YH, Chu CC, Tsai YH, Chao JC.. 2008. Curcumin or saikosaponin A improves hepatic antioxidant capacity and protects against CCl₄-induced liver injury in rats. *J Med Food.* 11:224–229. [[PubMed](#)] [[Google Scholar](#)]
103. Wu SJ, Tam KW, Tsai YH, Chang CC, Chao JC.. 2010. Curcumin and saikosaponin A inhibit chemical-induced liver inflammation and fibrosis in rats. *Am J Chin Med.* 38:99–111. [[PubMed](#)] [[Google Scholar](#)]
104. Wu SX, Sun HF, Yang XH, Long HZ, Ye ZG, Ji SL, Zhang L.. 2014. ‘Re-evaluation upon suspected event’ is an approach for post-marketing clinical study: lessons from adverse drug events related to *Bupleuri Radix* preparations. *Zhongguo Zhong Yao Za Zhi.* 39:2983–2988. [[PubMed](#)] [[Google Scholar](#)]

105. Xie H, Huo KK, Chao Z, Pan SL.. 2009. Identification of crude drugs from Chinese medicinal plants of the genus *Bupleurum* using ribosomal DNA ITS sequences. *Planta Med.* 75:89–93. [[PubMed](#)] [[Google Scholar](#)]
106. Xie JY, Di HY, Li H, Cheng XQ, Zhang YY, Chen DF.. 2012. *Bupleurum chinense* DC polysaccharides attenuates lipopolysaccharide-induced acute lung injury in mice. *Phytomedicine* 19:130–137. [[PubMed](#)] [[Google Scholar](#)]
107. Xie W, Bao Y, Yu LJ, Chen YY.. 2006. Effect of saikosaponins on glial fibrillary acidic protein expression in hippocampal astrocytes of pentetrazole-induced chronic kindling rats. *Nan Fang Yi Ke Da Xue Xue Bao*. 26:452–455. [[PubMed](#)] [[Google Scholar](#)]
108. Xie W, Yu YH, Du YP, Zhao YY, Li CZ, Yu L, Duan JH, Xing JL.. 2013. Saikosaponin A enhances transient inactivating potassium current in rat hippocampal CA1 neurons. *Evid Based Complement Alternat Med.* 2013:413092. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
109. Xue B, Zuguang Y, Baoqiang D, Qing Y, Yongqing X, Xiaohong L, Zelin L.. 1996. Antimalarial activities of *xiaochaihu tang* and its combination with artemisinin in mice infected with *Plasmodium berghei*. *Chinese J Exper Trad Med Formulae*. 2:7–10. [[Google Scholar](#)]
110. Yan J, Wei YF, Gu R.. 2014. Study on composition of essential oil in above-ground and root of *Bupleurum malconense* and root of *B. chinense* by AMDIS and retention index. *Zhongguo Zhong Yao Za Zhi*. 39:1048–1053. [[PubMed](#)] [[Google Scholar](#)]
111. Yao M, Yang J, Cao L, Zhang L, Qu S, Gao H.. 2014. Saikosaponin-d inhibits proliferation of DU145 human prostate cancer cells by inducing apoptosis and arresting the cell cycle at G0/G1 phase. *Mol Med Rep.* 10:365–372. [[PubMed](#)] [[Google Scholar](#)]
112. Ying ZL, Li XJ, Dang H, Wang F, Xu XY.. 2014. Saikosaponin-d affects the differentiation, maturation and function of monocyte-derived dendritic cells. *Exp Ther*

- Med. 7:1354–1358. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
113. Yoon SS, Kim HS, Cho HY, Yun J, Chung EY, Jang CG, Kim KJ, Yang CH.. 2012. Effect of saikosaponin A on maintenance of intravenous morphine self-administration. *Neurosci Lett.* 529:97–101. [[PubMed](#)] [[Google Scholar](#)]
114. Yoon SS, Seo JW, Ann SH, Kim HY, Kim HS, Cho HY, Yun J, Chung EY, Koo JS, Yang CH.. 2013. Effects of saikosaponin A on cocaine self-administration in rats. *Neurosci Lett.* 555:198–202. [[PubMed](#)] [[Google Scholar](#)]
115. You YJ, Lee IS, Kim Y, Bae KH, Ahn BZ.. 2002. Antiangiogenic activity of *Bupleurum longiradiatum* on human umbilical venous endothelial cells. *Arch Pharm Res.* 25:640–642. [[PubMed](#)] [[Google Scholar](#)]
116. Yu YH, Xie W, Bao Y, Li HM, Hu SJ, Xing JL.. 2012. Saikosaponin A mediates the anticonvulsant properties in the HNC models of AE and SE by inhibiting NMDA receptor current and persistent sodium current. *PLoS One.* 7:e50694. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]
117. Zhang BZ, Guo XT, Chen JW, Zhao Y, Cong X, Jiang ZL, Cao RF, Cui K, Gao SS, Tian WR.. 2014. Saikosaponin-D attenuates heat stress-induced oxidative damage in LLC-PK1 cells by increasing the expression of anti-oxidant enzymes and HSP72. *Am J Chin Med.* 42:1261–1277. [[PubMed](#)] [[Google Scholar](#)]
118. Zhang F, Chen L, Jin H, Shao J, Wu L, Lu Y, Zheng S.. 2015. Activation of Fas death receptor pathway and Bid in hepatocytes is involved in saikosaponin D induction of hepatotoxicity. *Environ Toxicol Pharmacol.* 41:8–13. [[PubMed](#)] [[Google Scholar](#)]
119. Zhao H, Li S, Zhang H, Wang G, Xu G, Zhang H.. 2015a. Saikosaponin a protects against experimental sepsis via inhibition of NOD2-mediated NF- κ B activation. *Exp Ther Med.* 10:823–827. [[PMC free article](#)] [[PubMed](#)] [[Google Scholar](#)]

120. Zhao J, Guo Y, Meng X.. 1987. The toxic principles of *Bupleurum longiradiatum*. Acta Pharm Sin. 22:507–511. [PubMed] [Google Scholar]
121. Zhao L, Zhang H, Bao J, Liu J, Ji Z.. 2015b. Saikosaponin-d protects renal tubular epithelial cell against high glucose induced injury through modulation of SIRT3. Int J Clin Exp Med. 8:6472–6481. [PMC free article] [PubMed] [Google Scholar]
122. Zhao W, Li JJ, Yue SQ, Zhang LY, Dou KF.. 2012. Antioxidant activity and hepatoprotective effect of a polysaccharide from *Bei Chaihu* (*Bupleurum chinense* DC). Carbohydr Polym. 89:448–452. [PubMed] [Google Scholar]
123. Zhou C, Liu W, He W, Wang H, Chen Q, Song H.. 2015. Saikosaponin a inhibits RANKL-induced osteoclastogenesis by suppressing NF- κ B and MAPK pathways. Int Immunopharmacol. 25:49–54. [PubMed] [Google Scholar]
124. Zhou H. 2003. A brief history of Bupleuri Radix research. Harbin, China: Heilongjiang University of Chinese Medicine Press. [Google Scholar]
125. Zhou X, Cheng H, Xu D, Yin Q, Cheng L, Wang L, Song S, Zhang M.. 2014. Attenuation of neuropathic pain by saikosaponin a in a rat model of chronic constriction injury. Neurochem Res. 39:2136–2142. [PubMed] [Google Scholar]
126. Zhu J, Luo C, Wang P, He Q, Zhou J, Peng H.. 2013. Saikosaponin a mediates the inflammatory response by inhibiting the MAPK and NF- κ B pathways in LPS-stimulated RAW 264.7 cells. Exp Ther Med. 5:1345–1350. [PMC free article] [PubMed] [Google Scholar]
127. Zuo ZP, Wang ZB, Gao Y, Guo YD, Wang BS, Su B, Song CC.. 2013. Bioactivity assay of *Bupleurum* injection for inhibiting PGE2 release *in vitro*. Zhongguo Zhong Yao Za Zhi. 38:3957–3960. [PubMed] [Google Scholar]

Formats:

- Article
- |
- [PubReader](#)
- |
- [ePub \(beta\)](#)
- |
- [PDF \(1.5M\)](#)
- |
- [Citation](#)

Share

-  [Facebook](#)
-  [Twitter](#)
-  [Google+](#)

Save items

[Add to Favorites](#)[View more options](#)

Similar articles in PubMed

- [Species discrimination of Radix Bupleuri through the simultaneous determination of ten saikosaponins by high performance liquid chromatography with evaporative light scattering detection and electrospray ionization mass spectrometry.](#) [J Chromatogr B Analyt Technol ...]
- [A comprehensive review and perspectives on pharmacology and toxicology of saikosaponins.](#) [Phytomedicine. 2018]
- [Ethanol extract of Bupleurum falcatum and saikosaponins inhibit neuroinflammation via inhibition of NF-κB.](#) [J Ethnopharmacol. 2015]
- [Visual detection of saikosaponins by on-membrane immunoassay and estimation of traditional Chinese medicines containing Bupleuri radix.](#) [Biochim Biophys Res Commun. 2006]
- [Radix Bupleuri: A Review of Traditional Uses, Botany, Phytochemistry, Pharmacology, and Toxicology.](#) [Biomed Res Int. 2017]

[See reviews...](#)[See all...](#)

Cited by other articles in PMC

- [New approach of medicinal herbs and sulfasalazine mixture on ulcerative colitis induced by dextran sodium sulfate](#) [World Journal of Gastroenterol...]
- [Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 \(SARS-CoV-2\)](#) [Journal of Medicinal Chemistry...]

- [Prophylactic and therapeutic roles of oleanolic acid and its derivatives in several diseases](#)[World Journal of Clinical Case...]
 - [Purposing Saikosaponins for the treatment of COVID-19](#)[Medical Hypotheses. 2020]
 - [A comprehensive review and perspectives on pharmacology and toxicology of saikosaponins](#)[Phytomedicine. 2018]
-

[See all...](#)

Links

- [Compound](#)
 - [MedGen](#)
 - [PubMed](#)
 - [Taxonomy](#)
-

Recent Activity

[Clear](#)[Turn Off](#)

- [A systematic review of the active saikosaponins and extracts isolated from Radix...](#)
-

A systematic review of the active saikosaponins and extracts isolated from Radix Bupleuri and their applications

Pharmaceutical Biology. 2017; 55(1):620

- [Radix isatidis Polysaccharides Inhibit Influenza a Virus and Influenza A Virus-Induced Inflammation via Suppression of Host TLR3 Signaling In Vitro](#)
-

Molecules. 2017 Jan; 22(1)

- [Chinese herbal medicine for coronavirus disease 2019: A systematic review and me...](#)
-

Chinese herbal medicine for coronavirus disease 2019: A systematic review and meta-analysis

Elsevier Public Health Emergency Collection. 2020 Oct; 160():105056

- [Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New...](#)
-

Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective

International Journal of Biological Sciences. 2020; 16(10):1708

- [Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in pa...](#)
-

Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial

Elsevier Public Health Emergency Collection ; 0

[See more...](#)

- [Bupleurum chinense DC polysaccharides attenuates lipopolysaccharide-induced acute lung injury in mice.](#)[Phytomedicine. 2012]
- [Saikosaponin-d inhibits proliferation of human undifferentiated thyroid carcinoma cells through induction of apoptosis and cell cycle arrest.](#)[Eur Rev Med Pharmacol Sci. 2014]
- [Mechanisms underlying the beneficial effects of Kaiyu Granule for depression.](#)[Neural Regen Res. 2013]
- [Cytotoxicity and anti-hepatitis B virus activities of saikosaponins from Bupleurum species.](#)[Planta Med. 2003]
- [Hepatoprotective effects of a chinese herbal formula, longyin decoction, on carbon-tetrachloride-induced liver injury in chickens.](#)[Evid Based Complement Alternat Med. 2013]
- [Saikosaponin-d affects the differentiation, maturation and function of monocyte-derived dendritic cells.](#)[Exp Ther Med. 2014]
- [Attenuation of neuropathic pain by saikosaponin a in a rat model of chronic constriction injury.](#)[Neurochem Res. 2014]

[See more ...](#)

- [Review \[A survey of the studies on saponins from Bupleurum in past 10 years\].](#)[Zhongguo Zhong Yao Za Zhi. 2002]
- [Review Putative genes involved in saikosaponin biosynthesis in Bupleurum species.](#)[Int J Mol Sci. 2013]
- [Cell type-specific qualitative and quantitative analysis of saikosaponins in three Bupleurum species using laser microdissection and liquid chromatography-quadrupole/time of flight-mass spectrometry.](#)[J Pharm Biomed Anal. 2014]
- [Curcumin or saikosaponin a improves hepatic antioxidant capacity and protects against CCl4-induced liver injury in rats.](#)[J Med Food. 2008]
- [Curcumin and saikosaponin a inhibit chemical-induced liver inflammation and fibrosis in rats.](#)[Am J Chin Med. 2010]

[See more ...](#)

- [Curcumin or saikosaponin a improves hepatic antioxidant capacity and protects against CCl4-induced liver injury in rats.](#)[J Med Food. 2008]
- [Curcumin and saikosaponin a inhibit chemical-induced liver inflammation and fibrosis in rats.](#)[Am J Chin Med. 2010]

- [Inactivation of cystein-aspartic acid protease \(caspase\)-1 by saikosaponin A.](#)[Biol Pharm Bull. 2011]
 - [Saikosaponin a and its epimer saikosaponin d exhibit anti-inflammatory activity by suppressing activation of NF-κB signaling pathway.](#)[Int Immunopharmacol. 2012]
 - [Saikosaponin A mediates the inflammatory response by inhibiting the MAPK and NF-κB pathways in LPS-stimulated RAW 264.7 cells.](#)[Exp Ther Med. 2013]
-

[See more ...](#)

- [Review Cystic Fibrosis from Laboratory to Bedside: The Role of A20 in NF-κB-Mediated Inflammation.](#)[Med Princ Pract. 2015]
 - [Curcumin or saikosaponin a improves hepatic antioxidant capacity and protects against CC14-induced liver injury in rats.](#)[J Med Food. 2008]
 - [Curcumin and saikosaponin a inhibit chemical-induced liver inflammation and fibrosis in rats.](#)[Am J Chin Med. 2010]
 - [Inactivation of cystein-aspartic acid protease \(caspase\)-1 by saikosaponin A.](#)[Biol Pharm Bull. 2011]
-

[See more ...](#)

- [Saikosaponin a inhibits RANKL-induced osteoclastogenesis by suppressing NF-κB and MAPK pathways.](#)[Int Immunopharmacol. 2015]
 - [Saikosaponin a inhibits lipopolysaccharide-oxidative stress and inflammation in Human umbilical vein endothelial cells via preventing TLR4 translocation into lipid rafts.](#)[Free Radic Biol Med. 2015]
-

[See more ...](#)

- [Saikosaponin a mediates the anticonvulsant properties in the HNC models of AE and SE by inhibiting NMDA receptor current and persistent sodium current.](#)[PLoS One. 2012]
 - [Saikosaponin a Enhances Transient Inactivating Potassium Current in Rat Hippocampal CA1 Neurons.](#)[Evid Based Complement Alternat Med. 2013]
 - [Attenuation of neuropathic pain by saikosaponin a in a rat model of chronic constriction injury.](#)[Neurochem Res. 2014]
 - [Effect of saikosaponin A on maintenance of intravenous morphine self-administration.](#)[Neurosci Lett. 2012]
 - [Effects of saikosaponin A on cocaine self-administration in rats.](#)[Neurosci Lett. 2013]
-

[See more ...](#)

- [Estrogen-like activities of saikosaponin-d in vitro: a pilot study.](#)[Eur J Pharmacol. 2010]

- [Induction of differentiation in rat C6 glioma cells with Saikosaponins.](#)[Phytother Res. 2002]
- [Antiviral effects of saikosaponins on human coronavirus 229E in vitro.](#)[Clin Exp Pharmacol Physiol. 2006]
- [Saikosaponin A inhibits influenza A virus replication and lung immunopathology.](#)[Oncotarget. 2015]
- [Saikosaponin a inhibits the proliferation and activation of T cells through cell cycle arrest and induction of apoptosis.](#)[Int Immunopharmacol. 2009]
- [Saikosaponin a and its epimer saikosaponin d exhibit anti-inflammatory activity by suppressing activation of NF-κB signaling pathway.](#)[Int Immunopharmacol. 2012]
- [Saikosaponin D disrupts platelet-derived growth factor-β receptor/p38 pathway leading to mitochondrial apoptosis in human LO2 hepatocyte cells: a potential mechanism of hepatotoxicity.](#)[Chem Biol Interact. 2013]

[See more ...](#)

- [Saikosaponin-d inhibits proliferation of human undifferentiated thyroid carcinoma cells through induction of apoptosis and cell cycle arrest.](#)[Eur Rev Med Pharmacol Sci. 2014]
- [Effects of SSd combined with radiation on inhibiting SMMC-7721 hepatoma cell growth.](#)[Med Sci Monit. 2014]
- [Saikosaponin-D enhances radiosensitivity of hepatoma cells under hypoxic conditions by inhibiting hypoxia-inducible factor-1α.](#)[Cell Physiol Biochem. 2014]
- [Saikosaponin-d inhibits proliferation of DU145 human prostate cancer cells by inducing apoptosis and arresting the cell cycle at G0/G1 phase.](#)[Mol Med Rep. 2014]
- [Cytotoxicity and anti-hepatitis B virus activities of saikosaponins from Bupleurum species.](#)[Planta Med. 2003]
- [Pharmacological evaluation of several major ingredients of Chinese herbal medicines in human hepatoma Hep3B cells.](#)[Eur J Pharm Sci. 2003]
- [The proliferative inhibition and apoptotic mechanism of Saikosaponin D in human non-small cell lung cancer A549 cells.](#)[Life Sci. 2004]

[See more ...](#)

- [Pharmacological evaluation of several major ingredients of Chinese herbal medicines in human hepatoma Hep3B cells.](#)[Eur J Pharm Sci. 2003]

- Saikosaponin-d suppresses the expression of cyclooxygenase-2 through the phospho-signal transducer and activator of transcription 3/hypoxia-inducible factor-1 α pathway in hepatocellular carcinoma cells.[Mol Med Rep. 2014]
-

[See more ...](#)

- Saikosaponin a and its epimer saikosaponin d exhibit anti-inflammatory activity by suppressing activation of NF- κ B signaling pathway.[Int Immunopharmacol. 2012]
 - Saikosaponin-D reduces cisplatin-induced nephrotoxicity by repressing ROS-mediated activation of MAPK and NF- κ B signalling pathways.[Int Immunopharmacol. 2015]
 - Saikosaponin-d attenuates ventilator-induced lung injury in rats.[Int J Clin Exp Med. 2015]
 - Saikosaponin D disrupts platelet-derived growth factor- β receptor/p38 pathway leading to mitochondrial apoptosis in human LO2 hepatocyte cells: a potential mechanism of hepatotoxicity.[Chem Biol Interact. 2013]
 - Saikosaponin d protects against acetaminophen-induced hepatotoxicity by inhibiting NF- κ B and STAT3 signaling.[Chem Biol Interact. 2014]
 - Inhibitory effects of saikosaponin-d on CCl4-induced hepatic fibrogenesis in rats.[World J Gastroenterol. 2007]
-

[See more ...](#)

- Saikosaponin a and its epimer saikosaponin d exhibit anti-inflammatory activity by suppressing activation of NF- κ B signaling pathway.[Int Immunopharmacol. 2012]
 - Saikosaponin D disrupts platelet-derived growth factor- β receptor/p38 pathway leading to mitochondrial apoptosis in human LO2 hepatocyte cells: a potential mechanism of hepatotoxicity.[Chem Biol Interact. 2013]
 - Saikosaponin D isolated from Bupleurum falcatum inhibits selectin-mediated cell adhesion.[Molecules. 2014]
-

[See more ...](#)

- Mechanistic study of saikosaponin-d (Ssd) on suppression of murine T lymphocyte activation.[J Cell Biochem. 2009]
- Saikosaponin-d affects the differentiation, maturation and function of monocyte-derived dendritic cells.[Exp Ther Med. 2014]
- Saikosaponin-d inhibits β -conglycinin induced activation of rat basophilic leukemia-2H3 cells.[Int Immunopharmacol. 2012]

- [Saikosaponin-D Reduces H₂O₂-Induced PC12 Cell Apoptosis by Removing ROS and Blocking MAPK-Dependent Oxidative Damage.](#)[Cell Mol Neurobiol. 2016]
 - [Type I saikosaponins a and d inhibit osteoclastogenesis in bone marrow-derived macrophages and osteolytic activity of metastatic breast cancer cells.](#)[Evid Based Complement Alternat Med. 2015]
 - [Saikosaponin C inhibits lipopolysaccharide-induced apoptosis by suppressing caspase-3 activation and subsequent degradation of focal adhesion kinase in human umbilical vein endothelial cells.](#)[Biochem Biophys Res Commun. 2014]
 - [Effects of Bupleurum scorzoneraefolium, Bupleurum falcatum, and saponins on nephrotoxic serum nephritis in mice.](#)[J Ethnopharmacol. 2008]
 - [Cytotoxicity and anti-hepatitis B virus activities of saikosaponins from Bupleurum species.](#)[Planta Med. 2003]
 - [Antiviral effects of saikosaponins on human coronavirus 229E in vitro.](#)[Clin Exp Pharmacol Physiol. 2006]
 - [Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.](#)[J Hepatol. 2015]
 - [In vitro anti-influenza A H1N1 effect of extract of Bupleuri Radix.](#)[Immunopharmacol Immunotoxicol. 2011]
 - [Bupleurum falcatum prevents depression and anxiety-like behaviors in rats exposed to repeated restraint stress.](#)[J Microbiol Biotechnol. 2012]
 - [Anti-infective and cytotoxic properties of Bupleurum marginatum.](#)[Chin Med. 2014]
-

[See more ...](#)

- [Effect of Bupleuri Radix extracts on the toxicity of 5-fluorouracil in HepG2 hepatoma cells and normal human lymphocytes.](#)[Basic Clin Pharmacol Toxicol. 2008]
 - [In vitro anti-influenza A H1N1 effect of extract of Bupleuri Radix.](#)[Immunopharmacol Immunotoxicol. 2011]
 - [Mouse single oral dose toxicity test of bupleuri radix aqueous extracts.](#)[Toxicol Res. 2012]
 - [Effect of saikosaponins and extracts of vinegar-baked Bupleuri Radix on the activity of β-glucuronidase.](#)[Xenobiotica. 2014]
 - [Antiangiogenic activity of Bupleurum longiradiatum on human umbilical venous endothelial cells.](#)[Arch Pharm Res. 2002]
-

[See more ...](#)

- Effect of Bupleuri Radix extracts on the toxicity of 5-fluorouracil in HepG2 hepatoma cells and normal human lymphocytes.[Basic Clin Pharmacol Toxicol. 2008]
- In vitro anti-influenza A H1N1 effect of extract of Bupleuri Radix.[Immunopharmacol Immunotoxicol. 2011]
- Effect of saikosaponins and extracts of vinegar-baked Bupleuri Radix on the activity of β-glucuronidase.[Xenobiotica. 2014]
- [Effect of saikosaponins on glial fibrillary acidic protein expression in hippocampal astrocytes of pentetetrazole-induced chronic kindling rats].[Nan Fang Yi Ke Da Xue Xue Bao. 2006]
- Saikosaponin d protects against acetaminophen-induced hepatotoxicity by inhibiting NF-κB and STAT3 signaling.[Chem Biol Interact. 2014]
- Ethanol Extract of Bupleurum falcatum Improves Functional Recovery by Inhibiting Matrix Metalloproteinases-2 and -9 Activation and Inflammation after Spinal Cord Injury.[Exp Neurobiol. 2010]
- Oleanene glycosides of the aerial parts and seeds of Bupleurum falcatum and the aerial parts of Bupleurum rotundifolium, and their evaluation as anti-hepatitis agents.[Chem Pharm Bull (Tokyo). 2011]
- Antidepressant-like effect of the methanolic extract from Bupleurum falcatum in the tail suspension test.[Prog Neuropsychopharmacol Biol Psychiatry. 2010]

[See more ...](#)

- Requirement for ERK activation in acetone extract identified from Bupleurum scorzonerifolium induced A549 tumor cell apoptosis and keratin 8 phosphorylation.[Life Sci. 2005]
- Anti-proliferative activity of Bupleurum scorzonerifolium in A549 human lung cancer cells in vitro and in vivo.[Cancer Lett. 2005]
- Acetone extract of Bupleurum scorzonerifolium inhibits proliferation of A549 human lung cancer cells via inducing apoptosis and suppressing telomerase activity.[Life Sci. 2003]
- Anti-infective and cytotoxic properties of Bupleurum marginatum.[Chin Med. 2014]
- The antiproliferative activity of saponin-enriched fraction from Bupleurum Kaoi is through Fas-dependent apoptotic pathway in human non-small cell lung cancer A549 cells.[Biol Pharm Bull. 2004]

[See more ...](#)

- Identification of crude drugs from Chinese medicinal plants of the genus Bupleurum using ribosomal DNA ITS sequences.[Planta Med. 2009]

- [Bioactivity assay of bupleurum injection for inhibiting PGE2 release in vitro].[Zhongguo Zhong Yao Za Zhi. 2013]
- Preparation of nasal temperature-sensitive in situ gel of Radix Bupleuri and evaluation of the febrile response mechanism.[Drug Dev Ind Pharm. 2010]
- A novel nasal delivery system of a Chinese traditional medicine, Radix Bupleuri, based on the concept of ion-activated in situ gel.[Arch Pharm Res. 2007]
- [Study on preparation procedure of Suppositoria Radix Bupleuri for kids].[Zhong Yao Cai. 2003]
- ["Re-evaluation upon suspected event" is an approach for post-marketing clinical study: lessons from adverse drug events related to Bupleuri Radix preparations].[Zhongguo Zhong Yao Za Zhi. 2014]
- ["Dose-time-toxicity" relationship study on hepatotoxicity caused by multiple dose of total Bupleurum saponin crude extracts to rats].[Zhongguo Zhong Yao Za Zhi. 2010]
- Saikosaponin D disrupts platelet-derived growth factor- β receptor/p38 pathway leading to mitochondrial apoptosis in human LO2 hepatocyte cells: a potential mechanism of hepatotoxicity.[Chem Biol Interact. 2013]
- Comparative research of different Bupleurum chinense composition to influence of hepatotoxicity of rats and oxidative damage mechanism].[Zhongguo Zhong Yao Za Zhi. 2009]
- Mouse single oral dose toxicity test of bupleuri radix aqueous extracts.[Toxicol Res. 2012]
- Review Pharmacology and toxicology of Bupleurum root-containing Kampo medicines in clinical use.[Hum Exp Toxicol. 2006]
- [The toxic principles of Bupleurum longiradiatum].[Yao Xue Xue Bao. 1987]
- Saikosaponin-d inhibits β -conglycinin induced activation of rat basophilic leukemia-2H3 cells.[Int Immunopharmacol. 2012]
- Isolation of an anti-complementary polysaccharide from the root of Bupleurum chinense and identification of its targets in complement activation cascade.[Chin J Nat Med. 2013]
- Chemical composition and biological activity of the essential oil obtained from Bupleurum marginatum (Apiaceae).[J Pharm Pharmacol. 2009]
- Antifungal activities and chemical composition of some medicinal plants.[J Mycol Med. 2014]
- Potential Therapeutic Role of Z-Isochailulactone in Lung Cancer through Induction of Apoptosis via Notch Signaling.[Evid Based Complement Alternat Med. 2012]

- Kaerophyllin inhibits hepatic stellate cell activation by apoptotic bodies from hepatocytes.[Liver Int. 2011]
-

[See more ...](#)

- ["Re-evaluation upon suspected event" is an approach for post-marketing clinical study: lessons from adverse drug events related to Bupleuri Radix preparations].[Zhongguo Zhong Yao Za Zhi. 2014]
 - Activation of Fas death receptor pathway and Bid in hepatocytes is involved in saikosaponin D induction of hepatotoxicity.[Environ Toxicol Pharmacol. 2016]
-

[Support Center](#)[Support Center](#)